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INTRODUCTION

Our laboratory has been interested in characterizing
the molecular etiology of Hodgkin's disease.

Hodgkin's

disease is an enigma since its description decades ago in
that little is known of the origin of the malignant cell,
the etiology and pathology of the disease, nor about the
molecular basis of tumorigenic transformation.

Because of

this lack of knowledge, diagnosis of the disease is
difficult, often leading to inappropriate treatment.

A

better understanding of this disease, particularly at the
molecular level, would help in the management of Hodgkin's
disease.
Recently, several groups showed that the Epstein-Barr
virus (EBV) genome is in the nucleus of Hodgkin's/ReedSternberg cells, suggesting a direct correlation between
EBV infection and the tumorigenic transformation of cells
to the Hodgkin's disease phenotype.

Based on these

observations, I hypothesized that the oncogenic events
responsible for EBV associated and non-EBV associated
Hodgkin's disease are mediated by aberrant expression of
cellular genes which are also aberrantly expressed in EBV
infected non-Hodgkin's lymphoma.

A key EBV encoded gene

involved in immortalization and potentially in
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transformation is the Epstein-Barr nuclear antigen 2 (EBNA
2).

My objective therefore was to isolate novel cellular

genes over-expressed in Hodgkin's-disease cells and which
are potential targets of EBNA 2 in EBV infected cells.

To

do so, I developed a differential screening procedure to
isolate such genes in an EBV negative Hodgkin's disease
cDNA library that hybridize to probes from EBNA 2
expressing African Burkitt's lymphoma cell line, but which
do not hybridize with probes from an African Burkitt•s
lymphoma cell line lacking EBNA 2.
The result of the screening procedure was the
isolation of a novel cDNA that we named ELAG (Early
Lymphoid Activation Gene) based on its transient
expression during activation of peripheral blood
mononuclear cells (PBMC) with either phytohemagglutinin
(PHA) or anti-CD3 monoclonal antibody.

Analysis of the

open reading frame suggests that ELAG may encode a nuclear
phosphoprotein.

I hypothesize that ELAG expression may be

required for the activation of other genes involved in the
T cell activation cascade.

Because ELAG is tightly

regulated during the activation and proliferation of
normal lymphoid cells, it would therefore be an ideal
candidate gene as a novel oncogene that when overexpressed may provide aberrant signals that are involved
in tumorigenic transformation.

3

Further investigation of ELAG may provide a better
understanding of the poorly understood yet highly
intricate regulation of T cell activation during the
immune response.

Additionally, characterization of the

normal function of ELAG may provide clues about its
potential role in tumorigenesis.

REVIEW OF RELATED LITERATURE

I. overview of the disease

Hodgkin's disease was originally characterized in
1832 by Thomas Hodgkin's in a paper describing the
clinical histories and postmortem observation of six
people with enlarged lymphatic glands (Kaplan, 1980).
Seventy years later Carl Sternberg and Dorothy Reed
described the characteristic giant multinucleate cells in
the diseased region of a Hodgkin's disease tumor.

This

malignant cell of Hodgkin's disease is now known as the
Reed-Sternberg cell.

In addition to the Reed-Sternberg

cell, a mononuclear variant cell is often identified in
diseased tissue.

The distinction between the mono- and

multi-nuclear cells is unclear and potentially represent
the same cell type.

Therefore, for the clarity in this

thesis the malignant cell in Hodgkin's disease tissue will
be referred to as the Hodgkin's/Reed-Sternberg cell (H/RS)
which refers to both the mono- and multinuclear cell.
The definition of Hodgkin's disease as a malignancy
has been controversial in the past because of the low
abundance of H/RS cells in the tumor (Kaplan, 1980).

The

H/RS cell often comprises less than 1% of the tumor mass
4
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while most of the tumor is comprised of non-neoplastic
infiltrate (Anastasi et al., 1987; Cossman et al., 1988).
The malignant nature of Hodgkin's disease was questionable
because of its pathology.

Close analysis of the H/RS

cells reveals characteristics similar to other tumor
cells.

H/RS cells in diseased lymph nodes are often

characterized by aneuploidy and clonality (Thangavelu and
Le Beau, 1989).

Additionally, tumors produced by

heterotransplantation into nude mice strongly resemble
Hodgkin's disease, a finding which supports the contention
that Hodgkin's disease is a malignancy (Diehl et al.,
1982; Schaadt et al., 1979).
Hodgkin's disease is characterized by a defect in
cellular immunity whereas humoral immunity remains
unimpaired (Twomey and Rice, 1980; Bjorkolm et al., 1982;
Fisher, 1982).

Patients with Hodgkin's disease have an

increased incidence of infection with opportunistic
pathogens including fungi, viruses, and tuberculosis
(Slivnick et al., 1989).

The H/RS cell is in an activated

state and secretes lymphokines which affect the immune
system (Borowitz et al., 1982; Maggi et al., 1988; Poppema
et al., 1982).

Patients in advanced stages of Hodgkin's

disease die of severe immunosuppression.
The etiology of Hodgkin's disease is poorly
understood.

Investigations by MacMahon showed a bimodal

age-specific incidence curve (MacMahon, 1957).

Analysis
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of the incidence curve shows a specific incidence peak for
individuals between the ages of 15 to 45.

Other

investigators suggested that Hodgkin's disease in younger
patients tends to be an inflammatory disease whereas
Hodgkin's disease in older patients is more similar to a
neoplasm.

MacMahon therefore suggested that Hodgkin's

disease may not be a single entity but a syndrome
comprising at least two entities with different
etiologies.
My goal was to investigate the molecular etiology of
Hodgkin's disease.

The impetus for the initiation of this

project stemmed from the lack of knowledge regarding the
cellular and molecular basis of Hodgkin's disease.
Because of this lack of information, diagnosis and
treatment are often difficult.

On the other hand,

Hodgkin's disease is curable when diagnosed early enough
and chemotherapy is initiated.

Therefore, a better

understanding of the molecular etiology might help us
understand how various drug therapies work and how to
improve them.

The discussion in this Literature Review

section addresses the current status of information
regarding Hodgkin's disease.

Additionally, I have

reviewed the recent literature on Epstein-Barr virus (EBV)
and its association with the Hodgkin's disease phenotype
that led to the initiation of this project.
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II. Characterizing and defining the Hodgkin's-disease cell

Hodgkin's disease remains an enigma in that it is
very poorly characterized.

Analysis of the histological

type and the cellular origin of the Hodgkin's-disease cell
has demonstrated that Hodgkin's disease is more
characteristic of a diverse range of cancers than of a
single disease entity.

A. Histopathology reveals a diversity of transformed cells
in Hodgkin's disease tissue
Hodgkin's disease is a diverse disease, and
therefore, pathologists have attempted to morphologically
and prognostically categorize the heterogeneous nature of
Hodgkin's disease.

Four histopathological classifications

have been proposed to categorize Hodgkin's disease tumors;
nodular sclerosis, mixed cellularity, lymphocytic
predominance, and lymphocytic depleted (Lukes, 1971; Lukes
and Butler, 1966a; Lukes et al., 1966b).

The histologic

subtype is not an independent prognostic factor if the
disease is treated appropriately.
Unequivocal diagnosis of Hodgkin's disease can only
be made by microscopic examination of one or more tissue
specimens (Anastasi et al., 1989).

However, it is often

difficult to make an accurate characterization and
diagnosis of the disease due to many factors specific to

8

Hodgkin's disease.

First, as described earlier, the

malignant cell often comprises a very low percentage of
the actual tumor mass (Anastasi et al., 1987; Cassman et
al., 1988).
cells.

Second, there are different types of H/RS

Malignant cells in a Hodgkin's disease tumor are

either mononuclear cells or contain multiple nuclei.
Additionally, cells similar to the H/RS cells are often
found associated with other pathological events such as
inflammatory lymphadenopathy and infectious mononucleosis.
Therefore, it is difficult to diagnose Hodgkin's disease
specifically based on the observation of a cell that looks
like a H/RS cell in a biopsy (Anastasi et al., 1989).

B. Origin of the Hodgkin's/Reed-Sternberg cell
The precursor cell of Hodgkin's disease is unknown.
Investigators have attempted to characterize the cellular
origin of the H/RS cell in lymphoid tissue and in cell
culture lines by utilizing immunohistochemical staining
and morphologic analysis.

Conflicting reports describe

the H/RS cell as a B lymphocyte (Taylor, 1974; Boecker et
al., 1975; Linch et al., 1985; Pinkus and Said, 1988), T
lymphocyte (Andreesen et al., 1984; Kadin, 1985),
monocyte-macrophage (Strauchen, 1984; Kadin, 1993;
Andreesen et al., 1989; Foon and Todd, 1986; Payne et al.,
1982), or as originating from an interdigitating reticulum
cell (Hansmann and Kaiserling, 1982; Kadin, 1982).
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Morphologic analysis of Hodgkin's disease lymph nodes
revealed ultrastructural similarities between H/RS cells
and either lymphocytes or interdigitating reticulum cells.
Both interdigitating reticulum cells and H/RS cells
function as antigen presenting cells, and lack
differentiation antigens characteristic of monocytes, and
pre-B or pre-T cells (Kadin, 1982; Stein et al., 1982).
However, interdigitating reticulum cells fail to stain
with monoclonal antibodies specific for surface markers of
H/RS cells, including HeFi-1 or Ki-1 (Schwarrting et al.,
1987; Stein et al., 1982).

Additionally, H/RS cells fail

to stain with monoclonal antibodies which specifically
bind reticulum cells including OKT6 (Stein et al., 1982;
Stein et al., 1983).
Investigations demonstrating that H/RS cells
positively stain for alpha-1 antitrypsin, alpha-1
antichymotrypsin, acid phosphatase, and Fe receptors led
some investigators to suggest that H/RS cells originate
from a monocyte/macrophage cell lineage (Strauchen, 1984;
Kadin, 1993; Andreesen et al., 1989; Foon and Todd, 1986;
Payne et al., 1982).

However, alpha-1 antitrypsin is also

expressed in activated lymphoblasts (Payne et al., 1982;
Jones et al., 1986).

Further, H/RS cells do not react

with monocyte specific antibodies and lack phagocytic
properties characteristic of macrophages (Stein et al.,
1982; Dorreen et al., 1984; Stein et al., 1986).
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Conversely, monocytes and macrophages do not react with
the Ki-1 monoclonal antibody (Jones et al., 1986;
Schwarrting et al., 1987; Stein et al., 1983).
Many recent investigations support the notion that
H/RS cells originate from lymphocytes.

Activated T cells

react with the monoclonal antibody anti-Leu-M 1, which
typically stains H/RS cells (Schwarrting et al., 1987;
Timens et al., 1986).

The presence of IL-2 (interleukin

2) receptors further support the contention that H/RS
cells are of lymphoid origin (Schwarrting et al., 1987).
Additionally, lymph node specimens have revealed the
presence of H/RS cells that react with pan B monoclonal
antibodies (Pinkus and Said, 1985; Timens et al., 1986).
An analysis of H/RS cells in tissue culture indicates
that there may be spectrum of cell types involved in the
development of Hodgkin's disease.

One study showed that

one Hodgkin's-disease cell line, L428 is comprised of
three morphologically distinct cells; larger multinucleate
Reed-Sternberg cells and medium size mono- or bi-nucleated
cells (Schaadt et al., 1979; Diehl et al., 1981).

It is

likely that the different subtypes of Hodgkin's disease
arise from different progenitor cells types (Slivnick et
al., 1989).

Efforts to characterize the lineage of the

H/RS cell will continue with the hope of improving the
efficiency of diagnosis.
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Several cellular genes are over-expressed in
association with Hodgkin's disease.

These genes include

CD30, CD15, CD74, CDw70 and interleukin-6 (IL-6) and IL-9.
However, these genes are expressed in a wide range of
tumor cell types and therefore there specific role in the
development of Hodgkin's disease is unclear.
Additionally, the cell surface markers are not
consistently expressed on all H/RS cells.

One study

showed that CD30 is expressed in H/RS cells of
approximately 70% of the Hodgkin's disease nodes tested
and CD15 was detected on only 65% of the diseased nodes
tested (Chu et al., 1992).

To date, there is no consensus

immunophenotype of the H/RS cell.

c.

Molecular basis of Hodgkin's disease
1. Cytogenetic abnormalities
Efforts to characterize the origin of the H/RS cell

have led to the identification of cytogenetic
abnormalities that are potentially specific for Hodgkin's
disease.

To better understand the molecular biology of

Hodgkin's disease and to provide data about the oncogenic
events, several investigators have tried to characterize
molecular anomalies that correlate with the transformed
phenotype.

Unique cytogenetic abnormalities that

demonstrate a high correlation with Hodgkin's disease or
Hodgkin's disease subtype have not been identified
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(Thangavelu and Le Beau, 1989).

This is in sharp contrast

to other hematopoietic tumors such as Burkitt•s lymphoma
and chronic myelogenous leukemia which demonstrate
distinct chromosomal alterations which are considered as
molecular hallmarks of these disease types.

Burkitt•s

lymphoma is characterized by a translocation of the c-myc
proto-oncogene with human immunoglobulin heavy chain
[t(8;14], kappa light chain (t(8;2], or the lambda light
chain genes (t(8;22] (Della-Favera et al., 1982; Taub et
al., 1982; Della-Favera et al., 1983; Adams et al., 1983;

Hollis et al., 1984; Davis et al., 1984; Pelicci et al.,
1986).

The translocation results in the constitutive

expression of the c-myc gene (Croce and Nowell, 1985;
Croce, 1987; Bishop, 1987).

CML is characterized by the

observation of the Philadelphia chromosome in which the cabl gene found on chromosome 9 is fused with the coding
sequences of the bcr gene (Rowley, 1973; de Klein et al.,
1982).

The resulting fusion gene is translated as a

chimeric protein with enhanced activity (Konopka and
Witte, 1985; Westbrook, 1988). However, the number of
cases studied may be too few to make any conclusions.
Further study of the H/RS cell may provide answers that
will eventually allow for the use of cytogenetic
aberrations as a prognostic marker, such as those
identified with non-Hodgkin's lymphomas.
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Anueploidy, or altered diploid number, is a common
characteristic of the H/RS cell (Fleishmann et al., 1976;
Hansmann et al., 1986; Hess et al., 1986; Kristoffersson
et al., 1987; Reeves and Pickup, 1980; Seif and Spriggs,
1967; Slavutsky et al., 1985).

Increased copy number of

chromosome 5 was characterized in over 25% of cases
studied (Thangavelu and Le Beau, 1989).

Additionally, a

gain of chromosomes 1,2,9,ll,12,16,18,20 and 21 occurred
in at least 10% of the cases.

The loss of chromosomes 10,

13, 17, 21 and 22 were observed in nearly 10% of all
cases.

Loss of chromosome 3 was never observed.

A review of the same cases described above showed
that structural alterations were identified which involved
chromosome arms lp (25%), lq (25%), as well as chromosome
arms 2q (16%), 6q (21%), llp (12%), llq(12%), and 14q
(12%).

Aberrant chromosomal banding patterns were

frequently found at positions lp21, 5pl5, llpl3, 14q32 and
18pll.

As discussed above, aberrations of chromosome band

14q32 are frequently found in B cell neoplasms (over 70%
of the cases), suggesting a B cell origin for these
particular cases of Hodgkin's disease.
In the study described here, I characterize a novel
gene from the Hodgkin's-disease cell line L428, which
might be deregulated in this cell type.

An understanding

of the karyotype of the L428 cell may eventually be
important in the interpretation of the results of the
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study described here because genes over-expressed in these
cells could potentially be deregulated due to a
translocation event.

The specific chromosomal aberrations

identified in the L428 were found at positions 2q33, 7q2236, llq21/23, 14q32, and 21q21-22.

As discussed above,

aberrations at position 7q35 are found at high frequencies
in T cell tumors while aberrations at position 14q32 are
frequently identified with B cell lymphomas.
2. Oncogenes in Hodgkin's disease
It is suspected that activation of proto-oncogenes
may be involved in the development of Hodgkin's disease.
Perhaps a translocation, as discussed above, may be
responsible for activating a proto-oncogene.

Other

potential mechanisms that may be involved include point
mutations (Bishop, 1987), over expression due to gene
amplification (Bishop, 1987; Marcu et al., 1992), or
inactivation of a tumor suppressor gene such as the
retinoblastoma gene (Rb) (Levine, 1993).
The difficulty in characterizing gene expression in
the H/RS cell of a diseased lymph node stems from the low
proportion of tumor cells to normal tissue.

Therefore,

several groups analyzed H/RS cell lines to determine if
any proto-oncogenes are consistently activated.
Jucker et al. analyze the expression of 20 protooncogenes in four H/RS cell lines (L428, L540, co, and
DEV) compared to their expression in normal hematopoietic
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cell (Jucker et al., 1990).

They found that c-myc, p53,

c-jun, pim-1, p56-lck, c-syn, c-raf and N-ras were each
expressed in at least three of the four cell lines tested.
Additionally, they observed that N-myc and p56-1ck were
only expressed in the CO cell line which also expresses T
cell receptor genes.
Specifically, the analysis of oncogene expression in
the L428 Hodgkin's-disease cell line showed that c-myc, cjun, c-syn, c-myb, c-met, pim-1, c-raf and p53 demonstrate
normal levels of expression (Jucker et al., 1990).

Other

proto-oncogenes tested including N-myc, L-myc, c-fos, csrc, c-fgr, p56-lck, c-mos were not detected.
Additionally, no mutations were identified in any of these
genes.

However, aberrant transcripts from the c-fes gene

were identified.

No point mutations were found in the Ki-

ras, H-ras or the N-ras gene.
More recent studies have used in situ hybridization
and immunohistochemical techniques to directly analyze
gene expression in the H/RS cells in diseased tissue.

One

study has shown that p53 is over-expressed in the H/RS
cell in 32% of the cases analyzed (Niedobitek et al.,
1993).

Their investigation did not reveal any specific

mutations in the gene but instead suggest that overexpression of this tumor suppressor gene may be an
indicator of altered wild-type p53 function.

Two

additional studies suggest a role of activated bcl-2 (Jiwa
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et al., 1993; Reid et al., 1993).

One study showed that

the both c-myc and bcl-2 are expressed in the H/RS cell in
72% of samples tested and suggested that these two
oncogenes may act in concert to affect the pathogenesis of
Hodgkin's disease (Jiwa et al., 1993).

III.

Epstein-Barr virus (EBV) and Hodgkin's disease

Since the original discovery of the virus by Epstein,
Barr and Achong (Epstein et al., 1964; Epstein and Barr,
1964; 1986), the Epstein-Barr virus (EBV) was found to
cause infectious mononucleosis and has become associated
with the development of Burkitt•s lymphoma (Epstein et
al., 1964; Epstein and Barr, 1964; 1986), nasopharyngeal
carcinoma (Hirayama and Ito, 1981; Fahraeus et al., 1988;
Chan et al., 1989; Tomei et al., 1987; Young et al., 1988)
and lymphoproliferative diseases induced in
immunosuppressed patients (Cen et al., 1993; Seiden and
Sklar, 1993; Purtilo et al., 1992).

It has long been

suggested that the Epstein-Barr virus (EBV) may also be
involved in the development of Hodgkin's disease.
Epidemiological studies supported this contention by
identifying a higher incidence of Hodgkin's disease among
people who had been afflicted with infectious
mononucleosis (Kaplan, 1980).

However, the association of
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EBV and Hodgkin's disease, without direct evidence,
remained questionable.
Studies by Sklar and colleagues showed in southern
blot analysis of biopsy tissue from Hodgkin's disease
patients that the EBV genome is harbored in the tumor mass
(Weiss et al., 1987).

However, because the H/RS cells

generally makes up less than 1% of the tumor mass, these
studies did not conclusively demonstrate the presence of
EBV in the H/RS cells.

These findings could have been the

result of an EBV infected B cell population in the lymph
node.
A later study by this same group utilized in situ
hybridization to directly demonstrate that the EBV genome
was harbored in the H/RS cell of disease lymph nodes in
20% of the Hodgkin's-disease patients tested
(Anagnostopoulos et al., 1989; Weiss et al., 1989).

These

findings supported the contention that EBV may be involved
in the development of Hodgkin's disease.

Similar studies

by other investigators showed that the EBV genome is
harbored in the H/RS cell of potentially 60% of the
patients tested (Staal et al., 1989; Libetta et al.,
1990).

One study which utilized PCR to detect EBV claimed

that as many as 78% of diseased nodes contained the EBV
genome (Herbst et al., 1990).

However these results are

dubious in that the sensitivity of PCR may allow for the
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detection of EBV in a small population of contaminating
non-H/RS cells.
I was interested in the association between EBV
infection and the development of Hodgkin's disease and
hypothesized that the oncogenic events responsible for
Hodgkin's disease, both EBV associated and EBV negative
independent Hodgkin's disease, are mediated by aberrant
expression of cellular genes which are also aberrantly
expressed in EBV infected non-Hodgkin's lymphoma.

My

objective was to develop a screening procedure to isolate
cellular genes that may be affected by the presence of EBV
and that contribute to the transformed phenotype of
Hodgkin's disease.

In order to describe the screening

method that I utilized, it is necessary to review the
molecular biology of the Epstein-Barr virus and what is
known about the role of EBV in tumorigenic transformation.

IV. Molecular basis for EBV immortalization and

transformation

A. The EBV genome
The Epstein-Barr virus was originally identified and
isolated from African Burkitt's lymphoma tumors (Epstein
et al., 1964; Epstein and Barr, 1964; 1986).

The EBV

genome of the virus is a double stranded DNA molecule of

19

approximately 173 kb (Baer et al., 1984).

It has been

cloned as a set of overlapping fragments of the
restriction enzymes EcoR I and BamH I and regions of the
genome are generally ref erred to by the name of the
corresponding BamH I fragment. The EBV genome potentially
encodes over 100 genes, however, the virus remains in a
latent state while expressing only a few EBV encoded
genes.

These include the following: the Epstein-Barr

nuclear antigens [EBNA] 1, 2a, 2b, 3a, 3b, Jc, 4, 5, and
6; the leader peptide, LP; the latent membrane proteins
[LMP] 1, 2a and 2b; and the EBV encoded RNAs EBER 1 and
EBER 2.

One gene recently described that is expressed

during the lytic phase is the EBV replication activator
ZEBRA (Baumann et al., 1993).

B. Expression of EBV encoded genes during latent infection
1. LCL phenotype
The in vitro EBV-infected B lymphocytes are
immortalized into lymphoblastoid cell lines (LCL) which
have gained the ability to proliferate in culture
indefinitely (Baichwal and Sugden, 1988; Rogers et al.,
1992; Middleton et al., 1991; Klein, 1989).
usually do not produce virus particles.

These cells

Instead the virus

remains in a latent state with only a small number of EBV
encoded genes being expressed.

Much of our understanding

about the pattern of EBV gene expression and the function
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of EBV encoded genes has come from studies of EBV infected
LCLs.
EBNA 1 is required for replication of the virus
(Yates et al., 1985; Lupton and Levine, 1985).

This is

the only viral protein consistently expressed in EBV
immortalized cells.

This protein specifically binds to

sequences at the origin of replication, to facilitate
replication (Lupton and Levine, 1985).

EBNA 1 has also

been shown to transactivate viral transcription from the

BamH I K-promoter of the EBV genome (Sugden and Warren,
1989) .
The role of EBNA 3a, 3b, Jc, 4, 5 and 6 are poorly
understood (Rogers et al., 1992).

However EBNA 3 proteins

have an affinity for single stranded DNA (ssDNA) while
EBNA 4 has an affinity for both single stranded DNA
(ssDNA) and double stranded DNA (dsDNA)
1989; Rogers et al., 1992).

(Rowe et al.,

The function of the non-

coding EBERs is unclear, but the presence of EBER is
recognizes as the most consistent indicator of latent EBV
infection (Raab-Traub and Flynn, 1986).

Additionally the

roles of the EBV encoded products in the development of
the transformed phenotype has not been distinguished.
Other latent proteins include EBNA 2, LMP, and the

BamH I A reading frame encoded proteins.

Because of the

association between these proteins and the ability of EBV
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to immortalize and transform cells, these proteins will be
discussed in a section addressing this important aspect.
The ZEBRA protein is translated from transcripts from
the EBV BamH I Z-fragment (BZLF 1).

Expression of this

protein alone is sufficient to activate the lytic cycle of
EBV infection (Baumann et al., 1993).

ZEBRA shares

homology with AP-1 transcriptional factors including Fos,
Fra-1, Jun, and Jun-B (Carey et al., 1992; Sato et al.,
1992).

This EBV encoded protein is able to bind to the

AP-1 site of the c-fos promoter and induce expression of
c-fos (Carey et al., 1992).

This protein binds the

canonical TRE/AP-1 site and therefore is potentially able
to transactivated several cellular genes.
2. Burkitt•s lymphoma
EBV was first discovered in a cell line derived from
Burkitt•s lymphoma tissue (Epstein et al., 1964; Epstein
and Barr, 1964; 1986).

The pattern of latency observed in

these cells in greatly restricted in that only EBNA 1 is
expressed (Rowe et al., 1987; Gregory et al., 1990) when
the cell lines are first established in culture.
Continued passage of these cells results in the
progression from this restricted pattern of latency to a
phenotype that more closely resembles an LCL.

When first

in culture, Burkitt•s lymphoma cell lines are classified
as type 1 (Burkitt•s lymphoma type) with a restricted
latency.

Type 2 cells have an intermediate latency
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pattern of EBV gene expression and type 3 develop an LCLlike phenotype (Altiok et al., 1992; Rowe et al., 1987;
Gregory et al., 1990).

Type 3 Burkitt's lymphoma cell

express most EBV latent proteins as well as cellular
antigens characteristic of an LCL.
3. Nasopharyngeal carcinoma and Hodgkin's disease
A third pattern of latency is exhibited in
nasopharyngeal carcinoma cells.

These cells express EBNA

1, LMP and transcripts originating from the BamH I open
reading frame (Gilligan et al., 1990).

Recent studies

have shown by in situ hybridization that EBV infected H/RS
cells express the same EBV encoded genes (Deacon et al.,
1993).

The role of these transcripts and the proteins

that they potentially encode is not known.

c. The role of EBV encoded genes in immortalization and
transformation
Although the ability of EBV to tumorigenically
transform human cells is likely due to the coordinate
activity of the latent proteins described above, the
direct immortalization and transformation is likely
triggered by two EBV encoded proteins; the Epstein-Barr
virus nuclear antigen 2 (EBNA 2) and the latent membrane
protein family (LMP 1, LMP 2a and LMP 2b).

The recently

identified transcripts originating from the BamH I Afragment may also be involved in transformation.
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1. BamH I A-open reading frame
A family of transcripts expressed in NPC cells,
originating from the BamH I A-region of the EBV genome
have recently been characterized (Gilligan et al., 1990).
The proteins translated in vitro from these transcripts,
32-kDa, 26-kDa, 17-kDa, 15-kDa, and 11-kDa, are poorly
characterized and their functions are unknown.

Similar

transcripts have been identified in the H/RS cells
infected with EBV (Deacon et al., 1993).
2. LMP proteins
The LMP is transcribed as a 2.6-kb RNA which is
spliced as a 2.4-kb mRNA containing a 1.3-kb open reading
frame.

The translated protein has six hydrophobic

transmembrane domains.
kDa protein.

The protein is translated as a 58-

Analysis shows that the LMP proteins form

patches on the cell surface indicating that it may be part
of a complex of proteins that may be necessary for
immortalization.
LMP 1 has been characterized as a true oncogene
(Moorthy and Thorley-Lawson, 1992; Niedobitek et al.,
1992; Wang et al., 1990).

Rodent fibroblast transfected

with this gene loose anchorage dependence acquire a
transformed phenotype (Wang et al., 1985; Wang et al.,
1988; Wang et al., 1985).

LMP 1 has been shown to act

with EBNA 2 to cooperatively induce expression of cellular
genes (Wang et al., 1990).

Despite the clear results of
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tissue culture studies, the biochemical function of LMP in
human cells and the development of human tumors is
unclear.

LMP 1 expression will induce the expression of

bcl-2 resulting in the protecting the cell from apoptosis
(Henderson et al., 1991).
LMP 2A and 2B have recently been identified
(Longnecker and Kieff, 1990).

These two proteins are

translated from alternatively spliced transcripts which
are translated as nearly identical proteins except that
the LMP 2A protein contains an additional 119 amino acids
at its amino terminus (Peng and Lundgren, 1993).

LMP 2A

has been found to co-localize to the cellular membrane
with LMP 1 (Longnecker and Kieff, 1990).
of this association is unclear.

The importance

The association of LMP 2B

with LMP 1 is only speculative at this time.

The function

of these two proteins are unknown.
3. EBNA 2
EBNA exists as two antigenically different proteins,
EBNA 2A and EBNA 2B, which share 50% amino acid homology
(Dambaugh et al., 1984; Addinger et al., 1985).

The

majority of EBV strains characterized to date encode EBNA
2A while EBNA 2B appears to be encoded by an EBV strain
which is restricted to areas of equatorial Africa (Rowe et

al., 1989).

Because EBNA 2A is the better characterized

protein, and in much of the literature EBNA 2 is
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synonymous with EBNA 2A unless otherwise mentioned, only
EBNA 2A will be addressed.
EBNA 2 is a key determinant of lymphocyte
transformation (Cohen et al., 1989; Cohen et al., 1992).
This protein shares homology with the three viral
oncogenes; adenovirus ElA, human papilloma virus-16 E7 and
SV40 large T antigen (Harada and Yanagi, 1991).

EBNA 2 is

a transactivator of viral genes such as LMP 1 (Reisman and
Sugden, 1986; Tsang et al., 1991; Tsang et al., 1991; Wang

et al., 1991b; Abbot et al., 1990) and cellular genes
(Cohen and Kieff, 1991; Rogers et al., 1992).

Infection

of B cells with EBV results in the expression of CD23
(Wang et al., 1990; Wang et al., 1987; Wang et al.,
1991a), CD21 (Calender et al., 1987), CD30 (Calender et

al., 1987), Bac-1 (Calender et al., 1987), and c-fgr
(Knutson, 1990).

Cells transfected with EBNA 2

demonstrate obvious changes observed during EBV infection
including increased growth in clumps.
The role of EBNA 2 in immortalization was clearly
demonstrated in studies comparing the viral strains of two
African Burkitt•s lymphoma cell lines; Jiyoye and P3HR-1.
The Jiyoye cell line was developed from the tumor cells of
an African Burkitt's lymphoma.

The cell is infected with

a strain of EBV that encodes EBNA 2B (Hinuma and Grace,
1967).

Virus isolated from tissue culture supernatants of

Jiyoye cells can infect peripheral blood B lymphocytes and
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result in the development of an immortalized cell line.
The P3HR-1 cell line is a tissue culture derivative of the
Jiyoye cell line (Hinuma and Grace, 1967).

The P3HR-1

viral strain, which lacks the gene encoding EBNA 2 due to
a spontaneous deletion, has lost the ability to
immortalize cells in culture (Jeang and Hayward, 1983;
Bornkamm et al., 1982).
It is hypothesized that EBNA 2 immortalizes cells by
inducing aberrant expression of cellular genes like CD30
and CD23 (Cordier et al., 1990; Calender et al., 1987;
Wang et al., 1987).

Furthermore, it is likely that these

cellular genes required for immortalization are expressed
in Jiyoye cell line but that the P3HR-1 cells no longer
expresses these cellular genes (Murray et al., 1988).
Based on this information, I developed a differential
screening method that would target cellular genes, like
CD23 and CD30 or any normal gene that is a target of EBNA
2 and that is expressed in Hodgkin's disease.

MATERIALS AND METHODS

I.

Isolation of a novel cDNA clone

A.

Analysis of transformed cell lines; development of the

differential screening protocol
All tissue culture cell lines were maintained in RPMI
1640 (Hazelton, Lenexa, KA) supplemented with 10% fetal
calf serum (Hazelton, Lenexa, KA), 50 U/ml penicillin
(Sigma, St. Louis, MO), 50 µg/ml streptomycin (Sigma, St.
Louis, MO) and 2 mM L-Glutamine (Sigma, St. Louis, MO).
The cells were stored in a humidified chamber at 37oc with
5% C02.

The Hodgkin's-disease cell line L428 was

originally described by Schaadt and collegues (Schaadt et

al. 1979; Schaadt et al., 1980), and was obtained from Dr.
R. Fisher (Department of Hematology/Oncology, Loyola
University - Chicago, Maywood, IL). The African Burkitt's
lymphoma cell lines Jiyoye and PJHR-1 were provided by Dr.
B. Sugden (Department of Oncology, University of Wisconsin
- Madison, Madison, WI).
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B.

Differential screening of the Hodgkin's-disease cDNA

library
1. L428 cDNA library
Highly purified poly A+ RNA was isolated from L428
cells and a cDNA library was prepared by Stratagene (La
Jolla, CA).

The library was packaged into the Lambda

ZAP™ vector.

The poly A+ RNA used to synthesize the cDNA

library was prepared as described in section IV.C.1 of the
Materials and Methods.
2. cDNA probes
In order to achieve the sensitivity required for
detection of genes expressed in low abundance, it was
necessary to produce the cDNA molecules that have
incorporated a high level of radiolabeled nucleotide.

The

procedure that I have developed to do so was a combined
protocol derived from methods previously described
(Gerard, 1988) and from personal communications with
several laboratories that are currently using this
procedure.

Whole cell poly A+ RNA was isolated from the

Jiyoye and P3HR-1 cell lines as described in the sections
below.

The cDNA was synthesized from the RNA according to

the following protocol.

Twenty micrograms of poly A+ RNA

was denatured in 20 µl of water at 65oc for 10 minutes.
The denatured RNA was then added to a tube containing 60
µl of the following solution: 50
potassium chloride, 8

mM

mM

Tris (pH 8.3), 40

magnesium chloride, 5

mM

OTT

mM
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(dithiothreitol), 500 µM of unlabeled dCTP, dGTP and dTTP,
10 µM of unlabeled dATP (Pharmacia, Piscataway, NJ) 1 µM
of [a32p]-dATP (ICN, Irvine, CA; specific activity
greater than 3000 Ci/mmol), and 120 units of RNasin
(Promega, Madison, WI).

The reduced molarity of the

unlabeled dATP is critical for the high level of
incorporation of the radiolabeled dATP in the synthesized
cDNA molecules.

Four thousand (4000) units of Mo-MuLV

derived reverse transcriptase (BRL, Bethesda, MD) were
added and the reaction was incubated at 42°C for three
hours.

The RNA template was hydrolyzed by the addition of

120 µl of a 150 mM solution of NaOH (to a final pH
and incubating at 10°c for 20 minutes.

=

10.5)

The solution was

then neutralized by the addition of 20 µl of 1 N HCl,
extracted twice with phenol, twice with phenol/chloroform,
twice with chloroform, and once with ether.

The cDNA was

then precipitated with ethanol using 0.2 M NaCl and two
volumes of ethanol at -a5oc for at least one hour and
pelleted by centrifugation.

The dried pellet was

resuspended in 30 µl of TE (pH 7.7), and purified from
non-incorporated nucleotides by G-50 Sephadex column
chromatography.

Determination of peak fractions

containing the cDNA was done with a hand held Geiger
counter.

I typically obtain probes with a specific

activity of greater than 109 cpm/µg.
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3. Library screening
The cDNA probes prepared above were used to screen
the L428 cDNA library packaged in Lambda Zap™
(Stratagene, La Jolla, CA).

standard screening procedures

were utilized (Sambrook et al., 1989).

Screening

protocols were designed so that a 150 mM diameter petri
dish would contain 2000 pfu when screening with cDNA
probes synthesized from both Jiyoye and P3HR-1 cell mRNA.
A 400 µl sample of a suspension of BB4 bacteria, grown to
an O.D.6oo = 0.5, were incubated with 600 µl of the Lambda
Zap™ library diluted in SM (50 mM Tris HCl [pH= 7.5],
100

mM

NaCl, 10

mM

Mgso 4 , 0.01% gelatin) buffer to yield

the pfu as described above.
37°c for 15 minutes.

The mixture was incubated at

To this mixture was then added 8 ml

of 0.7% top agarose made in NZYM (10 g/l casein amino
acids, 5 g/yeast extract, 10 g/l NaCl, 10 mM MgS04) media
that was previously sterilized and cooled to a temperature
of 40-45oc.

The tube containing the suspension was

quickly inverted several times to evenly suspend the
bacteria and poured directly onto a 1.5% NZYM agar plate.
Once solidified, the plates were incubated at 37°c until
the desired size of plaques developed (approximately five
to seven hours), and chilled at 4oc for one hour to harden
the top agarose.

Duplicate nitrocellulose filters were

laid on the plates.

The first filter was left on the

plate for two minutes, and the second filter was left on
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the plate for seven minutes.

Orientation of the filters

was achieved by piercing through both nitrocellulose and
agarose with an 18 gauge needle in an asymmetric pattern.
Filters were then incubated in a solution of 1.5 M NaCl
and 0.5 M NaOH for two minutes to denature the DNA,
neutralized by incubating in a solution of 1.5 M NaCl and
0.5 M Tris (pH 8.0) for five minutes, then washed in 0.2 M
Tris (pH 7.5) containing 2X SSC (0.3 M NaCl and 0.03 M
sodium citrate) for 30 seconds and dried completely.
were then baked under vacuum at 85°c for two hours.

They
The

filters were incubated in prehybridization buffer
containing 50% formamide, lX PIPES buffer, 0.5%

sos, and

0.5 mg/ml denatured salmon sperm DNA in sealed plastic
bags for at least one hour at 42°c.

The buffer was then

removed and replaced with 5 ml of fresh prehybridization
buff er and the radiolabeled cDNA probes were added to a
final concentration of 107 cpm/ml.

The filters were

hybridized with the probe at 42oc for 12-24 hours with
shaking and then washed according to the following
procedure that I have empirically developed to obtain
maximum signal to noise ratio:
2X SSC, 0.1%

twice in buffer containing

sos at room temperature for 10 minutes, twice

in the same buffer at 65°c for 20 minutes, and once in
buffer containing O.lX SSC, 0.1%
minutes.

sos at 65°c for 10

Washed filters were then exposed to X-ray film
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with intensifying screens at -8soc.

Hybridizing plaques

were isolated and rescreened to purify specific clones.

c. Characterization of cDNA clones
1. Rescue of cDNA clones
The cDNA inserts from the lambda Zap clones were
rescued into the plasmid pBluescript™ following the
procedure recommended by Stratagene.

Bacteria infected

with a lambda clone were incubated with the helper phage
R408 provided by Stratagene during which time the cDNA
insert was automatically excised and rescued into an EcoR
I restriction site in pBluescript.

The rescued insert in

pBluescript was transformed into XLl-Blue cells.

Plasmid

DNA was prepared by standard procedures (Sambrook, et al.,
1989).

The plasmid can be used directly to produce capped

transcripts suitable for in vitro translation (see below)
and for sequencing as described below.

The size of each

cDNA insert ligated into the plasmid vector, the plasmid
DNA was digested with EcoR I, separated by agarose gel
electrophoresis, stained with ethidium bromide, and
detected using a UV transilluminator.
2. Nucleotide sequencing and analysis
Complementary DNA (cDNA) inserts were sequenced in
both directions by dideoxy (Sanger) sequencing (Sanger et
al., 1977; Sanger et al., 1980) using a US Biochemical

Sequenase™ (Cleveland, OH)

kit.

Following instructions
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provided with the kit, 3 µg of double stranded plasmid DNA
was denatured in 0.2 N NaOH for five minutes, by the
addition of NH4AC to 0.8 M, and precipitated with two
volumes of absolute ethanol.

The DNA was pelleted, washed

with 70% ethanol, pelleted again, and briefly dried under
vacuum.
The oligomer used to prime the elongation reaction
was annealed to the denatured plasmid by resuspending the
dried DNA in 7 µl water, 2 µl of 5X Sequenase reaction
buffer (200 mM Tris-HCl [pH 7.5], 100 mM MgC1 2 , and 250 mM
NaCl] and 1 µl of primer (0.5 pmol/µl).
incubated at 37°c for 15 minutes.

The mix was

The elongation reaction

was initiated by adding 2 µl labeling buffer (7.5 µM of
each dCTP, dGTP, and dTTP), 1 µl of 0.1 M DTT, 0.5 µl
[a35s]-labeled dATP (New England Nuclear, Boston, MA),
and 2 µl of diluted Sequenase™ (1 unit/µl in 10 mM TrisHCl [pH 7.5], 5 mM DTT, and 0.5 mg/ml BSA).

The reaction

was divided into four tubes (labeled A, c, G, and T
respectively) incubated at room temperature for five
minutes.

Termination was accomplished by adding 2.5 µl of

the appropriate ddNTP mix (ddATP, ddCTP, ddGTP, or ddTTP)
into the respective tube and incubating for five minutes
at 37oc.

The sequencing reaction was stopped by the

addition of 4 µl of stop solution (95% formamide, 20 mM
EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol FF).
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Two microliters from each reaction was loaded per
well (formed using a sharkstooth comb) on an 8%
acrylamide-urea sequencing gel.

Electrophoresis was

carried out in Tris-boric acid buffer (TBE) at
approximately 60 watts constant power (sufficient to
maintain the gel at a constant temperature of 5o 0 c).
Following electrophoresis, gels were fixed in a solution
of 5% methanol and 5% acetic acid for 15 minutes, during
which time the urea was removed.
(30 minutes at

The gels were then dried

ao 0 c) under vacuum using a Hoffer Slab Gel

dryer (San Francisco, CA) and autoradiographed for 12 to
24 hours.

Each reaction was sufficient to resolve 250 to

300 base pairs of sequence from the primer.

Sequence data

from both stands of multiple clones was obtained to ensure
accuracy.

Primers specific for ELAG sequences were made

by the Macromolecular Analysis Facility at Loyola
University Medical School.
3. Computer analysis - GCG
The sequences were compared to the GenBank/EMBL
genetic sequence data bank using the GCG (Genetics
Computer Group; University of Wisconsin - Madison)
software maintained in the Loyola University department of
Academic Computing.
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D.

Confirmation of the 5' terminus
1.

Rescreening the library

To isolate insert cDNAs which were to be used as
probes in Northern blot and other hybridization analyses,
plasmid DNA was digested with EcoR I and DNA separated on
a 1% low temperature melting point agarose gel.

A 340-bp

EcoR I fragment (this fragment corresponds to ELAG 1 cDNA
sequences between positions 61 and 401; see Figures 4 and
20a) stained with ethidium bromide was localized using a
hand held long wave ultraviolet light source and excised
from the gel.

The gel was then cut into 3 mm squares and

placed into preweighed microfuge tubes, diluted with water
to a concentration of 0.3 g/ml, boiled for seven minutes
and stored at -2ooc.

This DNA was then radiolabeled with

[a32p]-dATP (ICN, Irvine, CA) using the Prime-a-Gene™
labeling kit (Stratagene, La Jolla, CA) in which DNA was
replicated with Klenow polymerase following initiation
with random primers.

Radiolabeled inserts were then

separated from non-incorporated nucleotides by G-50
Sephadex chromatography.
2.

5' RACE

Reverse transcription of first strand cDNA was
initiated with an ELAG sequence specific primer
reverse/complementary to the coding strand (5'-CATTTTCAAAATCTAGCCAGGC-3'; this sequence corresponds to
"primer 1" illustrated in Figure 5 and is reverse/
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complementary to sequence positions 657 through 678 shown
in Figure 4)).

In a standard microfuge tube, 20 ng of

poly A+ RNA was denatured in the presence of 2 pmol of
primer 1 at

1ooc in a volume of 14 µl for 10 minutes.

The

denatured RNA/primer mix was immediately chilled on ice
for one minute then centrifuged for 20 seconds to collect
the condensation.

Preparation of the reaction mixture was

completed by adding 2 µl of lOx synthesis buffer [200 mM
Tris-HCl (pH 8.4), 500 mM KCl, 25 mM MgC1 2 , 1 mg/ml BSA],
2 µl 0.1 mM OTT, 1 µl 10 mM dNTP mix [10 mM each dATP,
dCTP, dGTP, dTTP], and 1 µl of Superscript™ reverse
transcriptase (200 units/µ!).

The reaction was incubated

at 42oc for 30 minutes then stopped by warming to 55°c for
five minutes.

The template RNA was degraded by the

addition of 1 µl

~.

coli RNase H (2 units/µl) and

incubating at 55°c for an additional 10 minutes.
The first strand cDNA was separated from the salts,
unincorporated nucleotides and primers of the reverse
transcription reaction using the GlassMAx™ spin cartridge
supplied with the kit.

To the 21 µl reverse transcription

reaction, 95 µl of binding solution [6 M Na!] were added
and the contents transferred to a GlassMAx™ spin column
and centrifuged for 20 seconds at 13,000 x g.

The

cartridge was washed three times with 400 µl of ice cold
wash buffer and washed once with 400 µl of ice cold 70%
ethanol.

The cDNA was eluted by adding 50 µl DEPC
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(diethyl pyrocarbonate) treated water (pre-warmed to 65°c)
and by centrifugation at 13,000 x g for 20 seconds.
The addition of a poly(dC) tail was essential for the
PCR amplification of the cDNA products.

In a sterile

microfuge tube, 16 µl of purified cDNA were heated for 10
minutes at 7ooc, chilled on ice for one minute and
centrifuged to collect the condensation.

The tailing

reaction components were added which include 1 µl lOx
synthesis buffer (200 mM Tris-HCl [pH 8.4], 500 mM KCl, 25
mM MgC1 2 , 1 mg/ml BSA), 2 µl dCTP (2 mM), and 1 µl
terminal deoxynucleotidyl transferase (TdT; 10 units/µ!).
The reaction was incubated for 10 minutes at 37oc.

The

TdT was heat inactivated at 10°c for 10 minutes and the
reaction mixture placed on ice.
The targeted cDNAs were amplified in a reaction
containing 5 µl tailed cDNA, 30.5 µl DEPC-treated water, 5
µl lOx synthesis buffer (200 mM Tris-HCl [pH 8.4], 500 mM
KCl, 25 mM MgCl2, 1 mg/ml BSA), 1 µl 10 mM dNTP mix (10 mM
each dATP, dCTP, dGTP, dTTP), 1 µl of a modified ELAGspecific nested primer (10 µM; 5 1 -CAUCAUCAUCAUGGAAGTGTTTCTGATGGTAG-3'; this sequence corresponds to "primer 2 11 in
Figure 5 and is reverse/complementary to sequence
positions 315 through 334 shown in Figure 4) and 2 µl of
Anchor Primer (5'-CUACUACUAGGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG-3').

Four CAU triplet repeats were engineered onto

the 5' end of the ELAG specific primer to allow for rapid
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cloning into the pAMP-1™ plasmid vector.

The reaction

components were overlaid with oil and heated to 95°C for
five minutes.

Prior to starting the PCR cycles, 5 µl of

diluted Taq polymerase (0.4 units/µl, Perkin-Elmer Cetus)
were added to the reaction mixture below the oil.

The

cDNA was amplified for 40 cycles (94°c for 30 seconds,
55°c for 30 seconds, 12oc for 30 seconds).
3. Primer extension
Characterization of the transcriptional start site by
primer extension was done following the procedure
previously described (Makino et al., 1988).

Briefly, 2 µg

of poly A+ enriched RNA was denatured in 8 µl of DEPC
treated water containing 10 µM methyl mercury for 10
minutes.

The cDNA was reverse transcribed in a 50 µl

reaction containing the denatured RNA, 10 µl of 5x cDNA
synthesis buffer (500

mM

Tris [pH 8.3], 200

MgC1 2 ), 10 µl of dNTP mix (25

mM

mM

KCl, 50

mM

each dATP, dCTP, dGTP,

and dTTP; Pharmacia, Piscataway, NJ) and 1 µl of AMV
reverse transcriptase (2 units/µl; Seikagaku, Rockville,
MD), 28

mM

2-mercaptoethanol and 1 pmol of 5 1 end-labeled

primer (5'-GTTTTGCATCTATACCTCTCC-3'; this primer is
reverse/complementary to the sequence positions 146
through 126 shown in Figure 4).

The reaction was

incubated for one hour at 42°c, phenol/chloroform
extracted, ethanol precipitated and resolved on a standard
sequencing gel.
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The primer was end-labeled following standard
procedures {Sambrook et al., 1989) using (y-32p]-dATP
{6000 Ci/mmol; New England Nuclear, Boston, MA).

II.

Analysis of BLAG transcription by reverse

transcription/polymerase chain reaction

A. Peripheral blood mononuclear cells
All of the cell lines and normal peripheral blood
lymphocytes were cultured in RPM! 1640 {Hazelton, Lenexa,
KA) supplemented with 10% fetal calf serum {Sigma, st.
Louis, MO), 500 units/ml penicillin G {Sigma, St. Louis,
MO) and 50 µg/ml streptomycin sulfate {Sigma, st. Louis,
MO).

Cultures were maintained in a humidified incubator

at 37oc with 5% co 2 in 25 cm2 or 75 cm2 tissue culture
flasks or tissue culture plates.
1. Isolation
Venous heparinized blood was collected from normal
donors, diluted 1:1 with RPM! 1640 without serum, and 40
ml layered onto 10 ml of Histopaque™ {Sigma, st. Louis,
MO) separation medium.

The tube was centrifuged at 600 x

g and the layer containing the white blood cells collected
and washed in RPM! 1640.

Cell pellets were then either

frozen at -a5oc for RNA extraction from resting cells, or
cultured in vitro as described below.
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2. Activation
Mononuclear peripheral blood cells were aliquoted in
24 well tissue culture cluster plates (Costar, Cambridge,
MA) at a concentration of 1 x 106 cells/ml RPM! 1640
supplemented with 10% heat inactivated fetal calf serum
and incubated at 37oc with 5% co 2 with either 10 µg/ml of
phytohemagglutinin (PHA; Sigma, st. Louis, MO) or 50 µg/ml
anti-human Leu-4 monoclonal antibody (Becton-Dickenson,
San Jose, CA) which specifically binds to the CDJ molecule
(also referred to as anti-CDJ in this paper).

These

concentrations were previously determined to affect the
optimal cellular proliferation as measured by [JH]thymidine uptake analysis.
Cells from the Jurkat human T cell leukemic line were
incubated with the tumor promoter phorbol 12-myristate 13acetate (PMA; Sigma, St. Louis, MO) at a standard
concentration of 10 ng/ml, PHA (Sigma; St. Louis, MO) at
10 µg/ml or both at the concentrations indicated.

Cells

were harvest at four hours or 24 hours following
stimulation of the cells, washed in phosphate buffered
saline, and used for RNA isolation.
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B. Reverse transcription/Polymerase chain

reacti~n

-

CRT/PCR)
1. RNA preparation
For all procedures involving RNA, steps

wer~

taken to

minimize degradation of RNA by treating all solutions witb
DEPC followed by autoclaving and by baking all glassware
at 25ooc overnight.
Poly A+ RNA used in the RT/PCR studies was lsolated
from cell pellets using the QuickPrep™ Micro ~A
purification kit from Pharmacia (Piscataway, NJ) following
the suggested protocol.

Briefly, a cell pellet

~ontaining

107 cells was lysed in 400 µl of Extraction buff~r
(aqueous solution containing guanidinium thiocyanate and
N-lauroylsarcosine), and vortexed vigorously for one
minute.

The cell lysate was diluted in 800 µl of Elution

buffer (10 mM Tris-HCl (pH 7.4], 1 mM EDTA), and vortexed
for an additional minute.

The lysate was cleareq by

centrifugation at 13,000 x g for one minute and the
cleared homogenate was added to an oligo(dT)-cellulose
pellet prepared from 1 ml of slurry.

The homogenate and

oligo(dT) were mixed thoroughly for three minutes to
ensure efficient binding of RNA to the oligo(dT).

The

oligo(dT) was pelleted, washed five times with high salt
buffer (10 mM Tris-HCl (pH 7.4], 1 mM EDTA, 0.5

M NaCl),

twice with a low salt buffer (10 mM Tris-HCl [pH 7.4], 1
mM EDTA, 0.1 M NaCl), and transferred to a MicroSpin™

42

column.

The pellet was washed an additional two times in

the column.

The RNA was eluted by adding 70 µl of 65°c

elution buffer and centrifugation for five seconds at
13,000 x g.

The elution was repeated two more times to

ensure efficient removal of RNA.

RNA was stored at -a5°c.

2. Reverse transcription - cDNA synthesis
Complementary DNA (cDNA) was synthesized from cell
lines as well as resting and activated PBMCs using
modifications of standard protocols.

Twenty micrograms of

poly A+ RNA was denatured in 11 µl of water and 1 µl of
random hexamers (1 µg/µl; Pharmacia, Piscataway, NJ) at

10°c for 10 minutes, then chilled on ice for one minute
and centrifuged briefly to collect the condensation.
Reverse transcription was initiated by adding 4 µl of 5x
reaction buffer (500 mM Tris [pH 8.3], 200 mM KCl, 50 mM
MgCl2)

1

2 µl of dNTP mix (25 mM each dATP, dCTP, dGTP, and

dTTP; Pharmacia, Piscataway, NJ) and 1 µl of AMV reverse
transcriptase (2 units/µ!; Seikagaku, Rockville, MD) and
incubated at 42oc for 30 minutes.

The reaction was

terminated by heating to 1ooc for five minutes.

A control

reaction was prepared for each RNA sample tested by
assembling a standard reaction mixture and replacing
reverse transcriptase with water.
3. Polymerase chain reaction
Polymerase chain reaction (PCR) was done following
standard protocols with commercially available reagents.
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To enhance the efficiency and specificity of the reaction,
a hot start was used.

In the hot start procedure, each

reaction was assembled in a 0.5 ml PCR tube and contains
10 µl of lOx synthesis buffer (100 mM Tris-HCl [pH 9.0 at
25oc, 500 mM KCl, 1% triton x-100), 16 µl of MgC1 2 , 8 µl
of dNTP mix (10 mM each d.ATP, dCTP, dGTP, and dTTP;
Pharmacia, Piscataway, NJ), 1 µl of primer 1 (10 µM; 5'TCCCATCAAGCAGAGAAGTAG-31), 1 µl of primer 2 (10 µM; 5'CCAGTTGGAAAGTGTTTCTGATG-31).

The efficiency of each

reaction is highly dependent of the concentration of Mg++,
which I empirically determined to be 4 mM for the
reactions done in this lab.

Each reaction was covered

with an Ampliwax™ pellet (Perkin-Elmer Cetus, Norwalk,
CT), heated to aooc for three minutes to melt the wax,
then cooled to room temperature to solidify the wax.

Each

reaction mix was covered with 56 µl of water and 5 µl
diluted Taq polymerase (Promega, Madison, WI) and 5 µl of
cDNA.

As a control to determine that cDNA was made from

each RNA sample, 5 µl of cDNA was amplified using primers
(5'-GCCTGCCGTGTGAACCACGTGAC-3' and 5'-TACCTGTGGAGCAACCTGCTCAGA-31) which amplify a 277-bp segment of the Beta-2microglobulin gene (Lu et al., 1992).

All amplification

programs were initiated with a five minute incubation at
95oc to fully denature the cDNA template and primers.

The

standard program used for the RT/PCR experiments described
in this study was a three temperature cycle (95oc for 30
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seconds, 55oc for 30 seconds, and 12°c for 30 seconds).
The program concludes with a 10 minute incubation at 12°c
to ensure that all reactions are completed.

Each reaction

was supplemented with 1 µCi (a32p]-dATP (3000 Ci/mmol; New
England Nuclear, Boston, MA) to label the amplified
fragments of DNA.

Products were separated by

electrophoresis on a 2% agarose gel, dried, and
autoradiographed using an enhancing screen at

-as 0 c.

The linear range of amplification for the 277-bp
Beta-2-microglobulin segment and the 326-bp ELAG segment
from L428 cDNA were empirically determined following an
established protocol (Higuchi, 1990).

I determined that

the linear range of amplification for Beta-2-microglobulin
is between 22 and 30 cycles, while the linear range of
amplification of ELAG expressed in L428 cells is between
22 and 32 cycles.

All PCR reactions initiated to

specifically amplify a segment of the Beta-2-microglobulin
gene were amplified for 30 cycles.

However, it was

necessary to amplify ELAG products from activated PBMCs
for 36 cycles because of the relatively low level of ELAG
expression.
4. Southern blot hybridization.
PCR amplification of the ELAG specific segment was
carried out as described above except that the reaction
was done in the absence of radiolabeled dATP.

PCR

products were separated by agarose gel electrophoresis
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using standard methodology (Sambrook et al., 1989).
Following electrophoresis, the gel was denatured with 50
mM NaOH for 30 minutes, neutralized in 0.1 M Tris-HCl (pH

7.0) for 30 minutes and the DNA transferred to GeneScreen
Plus™ (NEN, Boston, MA) using a vacuum transfer apparatus
and lOX SSC.

The blots were denatured for 60 seconds in

50 mM NaOH, neutralized, and dried.

The membrane was then

incubated in pre-hybridization buff er containing 50%
formamide, 0.5 M NaCl, 10% dextran sulfate, and 20 µg per
milliliter denatured salmon sperm DNA for at least one
hour at 42°c.

The buffer was changed and the blots

hybridized with radiolabeled probes prepared from a 340-bp

EcoR fragment of ELAG cDNA.
changes of 2X SSC and 0.1%
65°c in O.lX SSC and 0.1%

Blots were washed in several

sos
sos.

at room temperature, and at
Autoradiography was done

to detect ELAG hybridizing genomic fragments.

III.

Characterization of the putative ELAG-enooded

protein

A.

Computer analysis
Analysis of open reading frames and structural motifs

was done using the MacVector software (IBI, New Haven,
CT).
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B.

In vitro translation
The ELAG transcripts were synthesized from linearized

plasmid containing cDNA which encodes the ELAG open
reading frame.

The cDNA inserts were cloned into the

pGEM™ (Promega, Madison, WI) vector and sequenced to
determine that transcription from the T7 RNA polymerase
promoter would produce the sense RNA strand.

The plasmid

was linearized by standard restriction digest using Sal I
which will cleave the plasmid in the polylinker region on
the 3 1 end of the insert.

Digested plasmid was analyzed

by electrophoresis on 1% agarose gel to verify the absence
of detectable non-linearized DNA.
In an RNAse-free microfuge tube, 1 µg of linearized
DNA template was combined with 2 µl of 2.5 mM
m7G(5')ppp(5')G cap analog (New England Biolabs, Beverly,
MA), 4 µl of 5x buffer (200 mM Tris-HCl [pH 7.9], 30 mM
Mgcl 2 , 10 mM spermidine, and 50 mM NaCl), 2 µl of 0.1 M
DTT, 3 µl of a nucleotide mix (which was 2 µM of ATP, CTP,
and UTP), 1 µl of 0.25 mM GTP, 0.5 µl RNasin, and 1 µl of
T7 RNA polymerase (20 units/µ!; Promega, Madison, WI) and
incubated for one hour at 37°c.

The concentration of GTP

was critical to efficient capping and was empirically
determined in our laboratory.

The amount of transcript

was estimated by electrophoresis in a 1% formaldehyde
containing agarose gel and staining with ethidium bromide.
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The in vitro translation was performed using a wheat
germ translation system (Promega, Madison, WI) following
the manufacturer's suggested protocol.

A 50 µl reaction

was assembled in an RNAse-free microfuge tube.

Five

hundred nanograms of RNA was denatured at 10°c for 10
minutes then immediately chilled on ice.

The components

of the translation reaction were added which include 25 µl
of wheat germ extract (in a buffer containing 107.5 mM
potassium acetate, 4.2 mM magnesium acetate, 5 mM 2mercaptoethanol, 10 mM DTT, 0.1 mg/ml tRNA, 1 mM
spermidine, HEPES (pH 7.5; the concentration of HEPES
buffer in the lysate is not provided by the company), 4 µl
of a 1 mM amino acid mixture minus cysteine, 2.5 µl [35s]cysteine (1200 Ci/mmole; New England Nuclear, Boston, MA),
0.5 µl RNasin (40 units/µ!), and 15.5 µl DEPC-treated
water.

The reaction was incubated at 25oc for one hour

and terminated by adding 50 µl of 2X Laemli sample buffer.

c. Mutagenesis
To test the ability of CUG to serve as the ELAG
translation initiation site, a CUG to TTA mutation in the
translational start site was created using a primer
mediated mutagenesis (Higuchi et al., 1988; Higuchi,
1990).

The procedure is illustrated in Figure 14.

Primers B (5'-GGGTGAGCAGAGTTACCAAGAGCAAAA-3 1 ) and

c (5'-

TTTTGCTCTTGGTAACTCTGCTCACCC-3') are complementary to each
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other; identical to the double stranded DNA between
positions 43 to 67 except that the CTG at position 55 was
changed to TTA on primer B.

Likewise, the CAG (reverse

complimentary to CTG) was changed to TAA (reverse
complimentary to TTA) on primer

c.

In the first two PCR

reactions primers A and B were used in a single reaction
while primers c and D were used in the other reaction.
The expected products would overlap and contain the
substitutions that allow for the CTG to TTA change.

The

PCR products were purified to remove unincorporated
nucleotides and primers by gel purification and elution
with the Magic PCR Prep™ system (Promega, Madison, WI).
The purification was done by electrophoresis in a 1% low
melting temperature gel.

The ethidium bromide stained

bands were excised, melted at 10°c for five minutes, then
diluted in 1 ml of PCR Prep resin (resin containing 7 M
guanidinium thiocyanate, and glass beads.).

The slurry

was collected in a column by vacuum and washed with 70%
isopropyl alcohol.

The DNA was eluted with 5 µl of water

and centrifuged at 16,000 x g for 30 seconds.

The

purified PCR products were introduced into a single PCR
(steps 2 and 3) reaction containing the outside primers; A
and D.

The mutated cDNA was purified again by gel

electrophoresis and separation from the agarose using
Magic PCR Prep™ (Promega, Madison, WI).

Purified cDNA

was subcloned into the pGEM™ PCR cloning vector (Promega,
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Madison, WI) in a ligation reaction containing 10 ng of
PCR product, 1 µl of vector (10 ng/µl)

1 µl of lOx ligase

buffer (300 mM Tris-HCl [pH 7.5], 100 mM MgC1 2 , 100 mM
OTT, 10 mM ATP), 1 µl of T4 DNA ligase, and water to a
final volume of 10 µl.

The ligation reaction was

incubated at 14oc overnight, then used to transform
competent

~.

coli cells by standard protocol.

The

subcloned cDNA insert was sequenced to confirm that the
intended bases were mutated.

IV.

Characterization of the transformation potential of

ELAG

A.

3 1 RACE
In an effort to compare the sequences of the ELAG

transcripts expressed in normal activated cells versus the
transformed Hodgkin's-disease cells, cDNA clones were
isolated using 3' RACE (Rapid Amplification of cDNA Ends).
Reverse transcription of the first strand cDNA was
initiated with a modified poly(dT) primer designated as
the Adapter Primer (5'-GGCCACGCGTCGACTAGTAC(T) 17 -3 1 ) .

The

Adapter primer (1 µl of a 10 mM solution) was added to 20
ng of poly A+ RNA in a total volume of 14 µl and denatured
at 10°c for 10 minutes.

The mixture was chilled on ice

for one minute and centrifuged to collect the
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condensation.

The remaining reaction components were

added which include 2 µl of lOx synthesis buffer,

[200 mM

Tris-HCl (pH 8.4), 500 mM KCl, 25 mM MgC1 2 , 1 mg/ml BSA],
2 µl 0.1 mM OTT, 1 µl 10 mM dNTP mix [10 mM each dATP,
dCTP, dGTP, dTTP], and 1 µl of Superscript™ reverse
transcriptase (200 units/µl).
degraded by adding 1 µl of

~-

The RNA template was
coli RNAse H (2 units/µl)

and incubated at 42°c for an additional 10 minutes.

The

condensation was collected by quick centrifugation.
The target cDNA was amplified in a reaction mixture
containing 5 µl of first strand cDNA, 39.5 µl DEPC-treated
water, 5 µl lOx synthesis buffer (200 mM Tris-HCl [pH
8.4], 500 mM KCl, 25 mM MgCl2, 1 mg/ml BSA), 1 µl of 10 mM
dNTP mix 1 µl 10 mM dNTP mix (10 mM each dATP, dCTP, dGTP,
dTTP), 1 µl of an ELAG-specific primer (5'-CAUCAUCAUCAUGCAAAAAGAAACCATTCATATC-3'; primer 1 illustrated in Figure
17 and contains ELAG sequences identical to sequence
positions 64 through 85 shown in Figure 4) prepared as a
10 µM solution, and 2 µl of the Universal Amplification
Primer (10 µM, 5'-CUACUACUACUAGGCCACGCGTCGACTAGTAC-3 1 ,
BRL, Bethesda, MD).

Four CAU triplet repeats were

engineered onto the 5' end of the ELAG-specific primer to
allow for rapid cloning into the pAMP-1™ plasmid vector.
The reaction components were overlaid with oil and heated
to 95°c for five minutes.

Prior to starting the PCR

cycles, 5 µl of diluted Taq polymerase (0.4 units/µl,
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Perkin-Elmer Cetus, Norwalk, CT) were added to the
reaction mixture below the oil.

The cDNA was amplified

for 40 cycles (94°c 30 seconds, 55oc for 30 seconds, 12°c
for 30 seconds).
The RACE products were cloned into the pAMP-1 vector
using the CloneAmp™ system (Gibco BRL, Bethesda, MD).
The plasmid pAMP-1 (1 µl containing approximately 50 ng)
was combined with 8 µl of amplified product from either a
5' or a 3' RACE reaction in a sterile microfuge tube.

To

the mixture, 1 µl of uracil DNA glycosylase (1 unit/µl)
was added and incubated for 30 minutes at 37oc.

Following

the subcloning procedure, 1 µl of the ligation mixture was
used to transform competent bacteria.

Clones containing

the ELAG DNA were identified by hybridization with an ELAG
probe, analyzed by restriction digest and gel
electrophoresis.

B. 5' RACE
The 5' terminal sequences of each clone isolated were
confirmed by 5' RACE using the same procedure as described
in section I.D.2 of the Materials and Methods.

The primer

used in this procedure to initiate reverse transcription
was 5'-TCCTCCAATGCAAGATCC-3' which is reverse
complementary to sequence positions 488 through 505 as
shown in Figure 18.

The ELAG primer used to amplify cDNA

products was 5'-CAUCAUCAUCAUGAATCACACATTGCATCGAG-3 1 which
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contains sequences that are reverse/complementary to
sequence positions 462 through 481 as shown in Figure 18.

c.

Northern blot analysis
1. Isolation of RNA
Whole cell RNA was extracted using modifications of

the procedure originally described previously (Chirgwin et

al., 1979).

Briefly, cell pellets were lysed in buffer

containing 4 M guanidinium thiocyanate (Fluka, Ronkonkoma,
NY), 0.5% sodium N-lauroylsarcosine, 25 mM sodium citrate,
and 0.1 M 2-mercaptoethanol, and lysate was then layered
over a 5.7 M CsCl (Schwartz-Mann, Cleveland, OH) cushion.
The RNA was pelleted through the CsCl at 30,000 RPM in a
SW41 Beckman rotor for 24 hours.

The RNA pellet was dried

and washed by ethanol precipitation.

Concentration of the

RNA was estimated by spectrophotometric analysis.
Definitive analysis of the quality of RNA was determined
by separating the RNA on formaldehyde containing agarose
gels and stained with ethidium bromide to detect the 28S
and 18S ribosomal bands.
Poly A+ RNA was enriched from RNA preparations by
oligo(dT) affinity chromatography using procedures as
adapted in our laboratory.

The whole RNA was resuspended

in 2 ml loading buffer containing 10 mM Tris (pH 7.0), 10
mM EDTA, 0.5% SOS, and 0.5 M NaCl and applied to a
oligo(dT) cellulose (BRL, Bethesda, MD) column
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equilibrated in the same buffer.

The solution containing

RNA was added to the column, the effluent collected and
added back to the column.
step was discarded.

The effluent following this

The column resin was washed

extensively with the loading buffer.

The bound mRNA

fraction was eluted with buffer containing 10 mM Tris (pH
7.0), 0.05%

sos

and 1 mM EDTA, peak fractions pooled, and

the mRNA precipitated with 0.2 M NaCl and ethanol at -asoc
for one hour.

The oligo(dT) resin was regenerated with

0.2 N NaOH and washed in loading buffer.

The mRNA was

collected by centrifugation, dried, resuspended in loading
buffer, and chromatography was repeated as before.
Enrichment of mRNA was assessed by formaldehyde containing
agarose gel electrophoresis of whole RNA, the effluent
ribosomal fraction, and the poly A+ enriched RNA fraction.
RNA was detected by ethidium bromide staining and the use
of a UV transilluminator.

I was typically able to achieve

greater than 90% enrichment of poly A+ RNA and used this
procedure to isolate RNA for the production of the L428
cDNA library.
2. Formaldehyde gel electrophoresis
The quality of RNA preparations was determined by
electrophoresis through formaldehyde containing agarose
gels following protocols outlined previously (Sambrook et
al., 1989).

Briefly, a 100 ml agarose (1% w/v) gel was

prepared by melting 1 g of agarose in 74 ml of water.

The
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agarose was allowed to cool to 6ooc, then 10 ml of lOX
MOPS buffer (0.2 M MOPS [pH 7.0], 80 mM sodium acetate,
and 10 mM EDTA [pH 8.0]), and 16 ml formaldehyde (final
concentration was 2.2 M) were added.

Gels were run at 100

volts in a lX MOPS buffer with constant recirculation to
maintain pH.

The RNA was denatured in 50% formamide, 2.2

M formaldehyde, and lX MOPS for 10 minutes at 65°c.

After

a denaturing step, lOX loading buffer (50% glycerol, 1 mM
EDTA [pH 8.0], 0.25% bromophenol blue, and 0.25% xylene
cyanol FF) was added to each sample.
3. Transfer and process
The procedure used in our laboratory for northern
blot analysis was a modification of standard procedures
(Sambrook et al., 1989).

Briefly, poly A+ RNA was

transferred from the formaldehyde gel onto a piece of
GeneScreen Plus™ (NEN, Boston, MA) using a vacuum blot
transfer apparatus and lOX SSC.
achieved in two hours.

Total transfer was

To remove formaldehyde and

renature the RNA, the membrane was then washed at room
temperature in 50 mM NaOH for 15 seconds, and then
neutralized in buffer containing lX SSC and 200 mM Tris
(pH 8.0) for 30 seconds.

The membrane was incubated in a

prehybridization solution containing 1 M NaCl, 1%
10% dextran sulfate for one hour at 65oc.

sos,

and

Hybridization

was done in fresh prehybridization solution supplemented
with 50 µg/ml sheared salmon sperm DNA and [32p]-labeled
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probe (1 x 106 cpm/ml) for 12 to 18 hours at 65oc.

Blots

were washed twice in buffer containing 2X SSC, 0.1% SOS at
room temperature for 10 minutes, twice in the same buffer
at 65°c for 20 minutes, and once in buffer containing O.lX
SSC, 0.1% SOS at 65oc for 10 minutes.

Washed filters were

then exposed to X-ray film with intensifying screens at 85°c.

v.

Transcriptional control of ELAG

A.

Screening the genomic library
The genomic library prepared from the WI-38 human

lung fibroblast cell line was purchased from Stratagene.
The library was packaged in the Lambda Fix™ vector.

The

library was screened following the procedure described in
section I.B.3 of Materials and Methods in which a 340-bp

EcoR I fragment from ELAG 1 was radiolabeled and used as a
probe.

This fragment (from sequence position 58 to 398

shown in Figure 4) contains most of the open reading
frame.

Plaque purified clones were amplified and the DNA

was harvested by the following method.
of~.

The KH803 strain

coli was infected with the phage at a 200:1 bacteria

to phage ratio in a 3 ml culture, and incubated while
shaking at 37°c for 20 minutes.
500 ml NZCYM broth in a 2L flask.

The culture was added to
This large culture was
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incubated at 37oc with shaking for approximately 10 hours
until complete lysis was observed.

NaCl was then

dissolved to a final concentration of 1 molar and the
culture chilled on ice for one hour.

The lysate was

cleared by centrifugation at 16,000 x g for 10 minutes at
4oc.

Phage were precipitated by adding polyethylene

glycol to the supernatant and chilling on ice.

The

precipitate was pelleted by centrifugation at 16,000 x g
for 10 minutes at 4oc.

The supernatant was discarded and

the pelleted phage particles were resuspended in 10 ml of
SM and 7.5 g of cesium chloride was dissolved.

The

suspension was centrifuged at 150,000g for 24 hours.

The

phage band was removed from the gradient and dialyzed
against a buffer containing 500 mM Tris-HCl (pH 7.7), 25
mM KCl, and 0.5 mM MgC1 2 .

The phage were then lysed by

adding EDTA, sos and Proteinase K (to a final
concentration of 50 mM, 0.5% and 100 µg/ml respectively)
and incubating at room temperature for 30 minutes.

The

mixture was phenol/chloroform extracted and ethanol
precipitated by adding sodium acetate to a concentration
of 300 mM and two volumes of ethanol.

The DNA was

resuspended in T.E. and digested with the various
restriction enzymes.

The restriction fragments were

separated by electrophoresis in a 1% agarose gel, stained
with ethidium bromide and analyzed.
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Restriction fragments containing sequences of
interest as indicated by hybridization studies were
subcloned into pBluescript™ by the following protocol.
Restriction enzyme digested DNA was separated on a 1% low
melting temperature agarose gel and stained with ethidium
bromide.

The bands of interest, including the

pBluescript™ vector linearized with the appropriate
enzyme, were localized using a long wavelength ultraviolet
light source, and excised.

An individual insert was

ligated into vector DNA in a reaction containing 5 µl of
water, 1 µl of melted agarose slice containing vector DNA
(approximately 50 ng), 4 µl of melted agarose slice
containing the intended insert and warming the tube for 10
minutes at 37°c.

The reaction mixture was completed by

adding 10 µl of a ligase cocktail containing 10 units of
T4 DNA ligase, 10 mM OTT, 10 mM ATP and ligase buffer (60
mM Tris-HCl [pH 7.8], 20 mM Mgcl 2 ).

The reactions were

incubated at 14°c overnight.

B. Bacterial strains and transformation
Our laboratory typically transforms

~-

coli strains

XLl-Blue, DH5-a, or JM109 with ligated plasmid DNA.

The

cells were made competent following a standard protocol.
A single colony was picked from an LB plate (LB + 15 µg/ml
of tetracycline was used for XLl-Blue) and used to
inoculate 5 ml of YA (5% Bacto yeast extract, 2% Bacto
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tryptone, 10 mM Mgso 4 , pH to 7.6 with KOH) and incubate
while shaking at 37°c to an O.D.550

=

0.3.

The culture

was added to 100 ml YA in a 1 liter flask and continued
shaking at 37oc until the culture attained a density of
O.D.550

=

0.48.

The culture was then chilled on ice for

five minutes and the cells pelleted by centrifugation at
1000 x g, 4°c, for five minutes.

The supernatant was

removed and the cells were resuspended in 40 ml ice cold
Tfbl (30 mM KAc, 100 mM KCl, 10 mM CaC1 2 , 50 mM MnCl2, 15%
glycerol, pH to 5.8 with acetic acid, sterilized by
filtration at 0.22µm).

Following a five minute incubation

on ice the cells were again pelleted at 1000 x g at 4°c
for five minutes.

The supernatant was removed and the

cells were resuspended in 4 ml ice cold Tfb2 (10 mM MOPS
[pH 6.5], 75 mM CaCl2, 10 mM KCl, 15% glycerol, sterilized
by filtration at 0.22µm).

The cells were incubated on ice

for an additional 15 minutes then aliquoted, flash frozen
in liquid nitrogen and stored at -85°c.

These cells

typically have an efficiency of approximately 1 x 107
cfu/µg of supercoiled DNA.
Transformation of competent cells was performed by
standard procedures.

Falcon 2054 tubes were pre-chilled

on ice for two minutes and 50 µl of thawed competent cells
were added to each tube.

Between 1 ng and 100 ng of DNA

were added to each aliquot and stored on ice for 30
minutes.

The cells heated to 42oc for 90 seconds and
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returned to ice for an additional two minutes.

The cells

were diluted in 950 µl of soc (2% Bacto tryptone, 0.5%
yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM
Mgso 4 , 20 mM glucose) and incubated with shaking at 37°c
for one hour.

The cells were then plated on LB (1%

Bactotryptone, 1% NaCl, 0.5% Bacto Yeast extract)
containing agar and supplemented with the appropriate
antibiotic.

RESULTS

I. Isolation and sequence of a novel cDNA clone

A. Screening protocol
Based on recent evidence associating Epstein-Barr
virus (EBV) infection with the development of Hodgkin's
disease (Anagnostopoulos et al., 1989; Weiss et al., 1989;
Staal et al., 1989; Libetta et al., 1990), I hypothesized
that the oncogenic events responsible for Hodgkin's
disease, both EBV associated and non-EBV associated
Hodgkin's disease, are mediated by aberrant expression of
cellular genes which are also aberrantly expressed in EBV
infected non-Hodgkin's lymphoma.

My objective therefore,

was to isolate cellular genes highly expressed in
association with Hodgkin's disease and EBV infected
Burkitt•s lymphomas in order to begin elucidating the
signal transduction pathways responsible for the
transformation events in Hodgkin's disease.

When I

initiated this study, the CD30 gene had been associated
with the Hodgkin's disease phenotype and had been shown to
be expressed in some EBV infected Burkitt's lymphoma
cells.

Therefore, I was interested in isolating this

gene, or any novel gene potentially involved in the
60
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tumorigenic transformation of cells to the Hodgkin's
disease phenotype.
To do so, I developed a screening procedure that
would identify genes expressed in an EBV negative
Hodgkin's-disease cell and that are potential cellular
targets of the EBV encoded nuclear antigen 2 (EBNA 2).
EBNA 2 is a viral gene important for inducing cellular
immortalization (Cohen et al., 1989; Cohen et al., 1992).
The differential screening protocol employed the use of
three cell lines; L428, Jiyoye, and PJHR-1.

Some

characteristics of these cell lines which are relavant to
the screening procedure are summarized in Table 1.

The

L428 cell line is an accepted tissue culture derivative of
the Hodgkin's disease/Reed-Sternberg cell (H/RS)

et al., 1986; Drexler and Minowada, 1992).

(Drexler

The cell line

was derived from the pleural effusion of a Hodgkin's
disease patient (Schaadt et al., 1980).

Several cellular

proteins commonly associated with Hodgkin's disease are
expressed by this cell line including CD30 (Schwab et al.,
1982; Stein et al., 1985; Nawrocki et al., 1988) and IL-9
(Gruss et al., 1992).

Characterization of EBNA expression

shows that the L428 cell line is not infected with EBV
(Schaadt et al., 1980).

The Jiyoye cell line was

established from an African Burkitt•s lymphoma (Hinuma and
Grace, 1967).

The cell is infected with a strain of EBV

that encodes EBNA 2.

Virus isolated from tissue culture
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TABLE 1

EBV

EBNA 2

African Burkitt•s
lymphoma

+

+

African Burkitt's
lymphoma

+

CELL LINE

DESCRIPTION

L428

Hodgkin's disease

Jiyoye
P3HR-1

Characteristics of the cell lines utilized in the
differential screening procedure. EBV, Epstein-Barr
virus; EBNA-2, Epstein-Barr nuclear antigen 2.
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supernatants of Jiyoye cells infects and immortalizes
peripheral blood B lymphocytes.

The P3HR-1 cell line is a

tissue culture derivative of the Jiyoye cell line (Hinuma
and Grace, 1967).

These cells are infected with a strain

of EBV that lacks the gene encoding EBNA 2 due to a
spontaneous deletion (Jeang and Hayward, 1983; Bornkamm et

al., 1982).

Virus isolated from the tissue culture

supernatants of P3HR-1 cells can infect peripheral blood B
lymphocytes, but the infected cells will fail to become
immortalized (Jeang and Hayward, 1983; Bornkamm et al.,
1982).

Additionally, the Hodgkin's-disease related CD30

is expressed in the Jiyoye cell line but not in the P3HR-1
cell line.
The differential screening procedure used is
diagramed in Figure 1.

The cDNA library from the EBV

negative, Hodgkin's-disease cell line L428 was screened by
standard protocols with some modifications as described in
the Materials and Methods section.

Duplicate

nitrocellulose filters were prepared from the library.
One of the nitrocellulose filter was hybridized with high
specific activity [32p]-labeled cDNA probes from the
Jiyoye cell line.

The duplicate filter was hybridized

with cDNA from the P3HR-1 cell line.

Following

hybridization and washing, the nitrocellulose discs were
autoradiographed.

In the hypothetical autoradiographic

constellation illustrated in Figure 1, the clone in the
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L42B cONA Library

~licate

e

•

lifts

Autoradiogaphy

•

•
•

•
•

FIGURE 1. Schematic diagram of the differential screening
protocol. The cDNA library prepared from the Hodgkin'sdisease cell line L428 was differentially screened by
preparing duplicate lifts on nitrocellulose filters, and
hybridizing one nitrocellulose filter with high specific
activity cDNA from the Jiyoye and hybridizing the
duplicate filter with cDNA probes from the PJHR-1 cell
line. The hypothetical autoradiographs shown in this
figure illustrate a clone that specifically hybridizes
with the Jiyoye probe and that would be a target for
further study.
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center of the filter hybridized with Jiyoye cDNA
represents a gene expressed in common between Jiyoye and
L428 but not in PJHR-1.
Clones isolated by this method were tested to
determine if they meet three criteria:
interested in novel genes.

1) I was

One such gene of interest was

the CDJO gene, which at the time of the screening had not
been isolated; 2) isolated clones should also be expressed
in association with Hodgkin's disease and EBV mediated
transformation; 3) finally, I was interested in clones
expressed in association with normal lymphoid cell growth,
not housekeeping genes, since many transformation
associated genes are normally involved in growth and
proliferation (Bishop, 1987).

B. Sequence analysis
To satisfy the first criteria described above, clones
isolated by the differential screening procedure were
partially sequenced.

Three clones which were selected

following three rounds of differential screening were
rescued into the pBluescript™ plasmid.

The cDNA inserts

were sequenced by the Sanger chain termination method
using primers for the T7 RNA polymerase promoter on the
plasmid vector.

Sequences were compared with the

GenBank/EMBL data bases using the GCG computer software.
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Partial sequences of two clones isolated by differential
screening are shown in Figure 2.

A clone designated as H4

was compared to the data base and the best match is shown
in Figure 2A.

The results show that the sequence between

position 3 and 122 were nearly identical to the sequence
of the HLA-Cw2 heavy chain gene between positions 4013 and
3840.

Only two mismatches were identified (positions 13

and 101 of the H4 clone).

Close analysis of the

autoradiograph with the actual sequence data from the H4
clone indicates that these mismatches are potentially due
to sequencing errors (data not shown).

The numerical

positions of the HLA clone are shown in descending order.
Additionally, the HLA sequences shown in this figure are
complementary to published sequences between positions
3840 and 4013 (Parham et al., 1989).

These results taken

together indicate that the computer generated comparison
has aligned the partial sequence of the H4 clone with the
3 1 terminus of the HLA sequence and therefore, H4 is
probably not a novel clone.
A clone designated as F2T3 was compared to the data
base and the best match is shown in Figure 2B.

The

results show that the sequence between position 1 and 88
were nearly identical to the sequence of the mitochondrial
encoded cytochrome oxidase III (COIII) gene between
positions 9990 and 9903.

Four mismatches were identified

(positions 43, 44, 51, and 83 of the F2T3 clone).

Close
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F2T3.Txt
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Human mitochondrion, complete gonome,. 6/89
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88 TTTGGC.TCGAAGCCGCCGCCTGATACTGGCAT'l"l'TGTAAGATGTCCTTT 40
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9903 TTTGGC'I'TCGAAGCCGCCGCCTGATACTGGCAT'l"l'TGT.AGATGTGGTI'T 9951

.

.

39 GACTATI'TCTGTATGTCTCCATCTATTGATGAGGGTCTT l
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9952 GACTATI'TCTGTATGTCTCCATCTATTGATGAGGGTCTT 9990

FIGURE 2. Partial nucleotide sequences of two clones
isolated by differential screening of the L428 cDNA
library compared with sequences in the GeneBank/EMBL data
base. Panel A. Sequences of the clone designated H4 (base
pairs 3 to 178) shares the greatest level of homology with
HLA-Cw2 heavy chain gene sequences (base pairs 4013 to
3840). Panel B. Sequences of the clone designated F2T3
(base pairs 1 to 88) shares the greatest level of homology
with the mitochondrial encoded cytochrome oxidase III gene
(base pairs 9990 to 9903).
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analysis of the autoradiograph with the actual sequence
data from the F2T3 clone indicates that these mismatches
are potentially due to sequencing errors (data not shown).
The numerical positions of the COIII clone are shown in
descending order and the sequences shown in this figure
are complementary to published sequences of the COIII gene
(Montoya et al., 1981; Ojala et al., 1981).

These results

taken together indicate that the computer generated
comparison has aligned the partial sequence of the F2T3
clone with the 3' terminus of the COIII sequence and
therefore F2T3 is not likely to be a novel clone.
However, sequence analysis of a third clone,
designated ED1T7, suggested that it might be novel.

As

shown in Figure 3, the partial sequence of this clone
between base positions 1 and 104 was most closely related
to the Dictyostelium discoideum encoded cyclic nucleotide
phosphodiesterase between base positions 3486 and 3574.
The computer generated comparison shows that only 43 of
104 base pairs of the ED1T7 clone sequence matched the
sequence of the phosphodiesterase gene.

Because this

clone showed less than 50% sequence identity with the D.

discoideum phosphodiesterase gene, the ED1T7 clone
appeared to be novel.

A rigorous sequencing analysis was

done to confirm this observation.

The entire nucleotide

sequence was determined by analyzing multiple
independently isolated clones from the L428 Hodgkin's-
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Edlt7.Txt
check: 7929 from: 1
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Dictyostelium discoideum, cyclic nucleotide phosphodiesterase. 6/89
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FIGURE 3. Partial sequences of the clone designated ED1T7
{l to 104) shares the greatest level of homology with the
Dictyostelium discoideum encoded cyclic nucleotide
phosphodiesterase.
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FIGURE 4. Complete nucleotide and predicted amino acid
sequence of the EDl cDNA isolated by differential
screening of the Hodgkin's-disease cell line L428 cDNA
library. Base pairs 1 through 55 (underlined) were
identified using 5' RACE.
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disease cell line.

The full length clone, designated EDl,

which corresponds to base pair positions 56 through 1824
on Figure 4, was compared with the data base.

The search

again showed no direct match with any sequences which
strongly suggested that the cDNA represented a novel gene.
The complete nucleotide and predicted amino acid sequence
of this cDNA clone is shown in Figure 4.

The sequence of

the base pairs 1 through 55 were determined using 5 1 RACE
as described below.

c.

Characterization of the 5 1 terminus of EDl
In preliminary sequence analysis I could not identify

an ATG translational start site.

Therefore, I speculated

that the cDNA clone isolated in the differential screening
procedure was not full length, lacking the sequences at
the 5' terminus containing an ATG start site.

Three

methods were used to identify and characterize the 5'
terminus of the EDl cDNA.

First, the L428 cDNA library

was rescreened using EDl specific probes in order to find
longer cDNA clones.

In the second approach I attempted to

specifically isolate the 5 1 terminus of the EDl clone as
well as the related clones by RACE (Rapid Amplification of
cDNA Ends).

Finally, primer extension was done to confirm

the position of the 5 1 terminus.
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1. Rescreening the L428 cDNA library
The Hodgkin's disease cDNA library was rescreened
using an EDl specific probe in an effort to identify the
most full length EDl clones.

All of the EDl cDNA clones

contained similar 5 1 termini but still no ATG
translational start site was identified.

Interestingly,

several unique clones with sequences related to EDl were
isolated from the L428 cDNA library.

A description of

these clones and their potential involvement in the
transformed phenotype will be discussed in section IV of
the Results.
2. 5 1 RACE
RACE (Rapid Amplification of cDNA Ends) was used as a
second approach to directly isolate the 5' terminus of the
EDl cDNA.

Figure 5 illustrates the 5' RACE procedure.

In

the first step, cDNA synthesis was initiated with a primer
(reverse/complementary to base pair positions 657 through
678 of EDl as shown in Figure 4) specific for the EDl
clone.

The design of the this primer was based on

sequences obtained from the cDNA clone isolated from the
L428 Lambda ZAP library.

A poly(dC) tail was added to the

3 1 terminus of the cDNA molecules.

The tailed cDNA

molecule was then PCR amplified using a poly(dG) primer
and nested primer (reverse/complementary to base pair
positions 315 through 334 of the EDl sequence as shown in
Figure 4; this primer has a modified tail that allows for
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5' RACE
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1
1
1

Step 1

~

AAAAAAA

Step 2

~
Step 3

0

FIGURE 5. Schematic diagram of the 5 1 RACE procedure used
to isolate the 5' terminus of the EDl cDNA. Rapid
Amplification of cDNA Ends (RACE) was used to isolate the
5' terminus of the EDl cDNA. In this procedure, cDNA
synthesis was specifically initiated using an oligomer
(primer 1) complementary to the coding strand of the
clone. A poly(dC) tail was added to the 3 1 terminus of
the synthesized cDNA clones. The tailed clones are PCR
amplified using a primer containing a poly(dG) segment and
primer 2 which was complementary to the coding strand.
PCR products are subcloned and sequenced as described in
Materials and Methods.
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rapid cloning into the pAMP-1™ vector which is described
in the Materials and Methods section) specific for EDl
sequences.

The RACE products were ligated into the pAMP-1

plasmid vector and sequenced.

Sequence analysis of the

longest RACE clone allowed for the characterization of an
additional 55 base pairs of EDl cDNA sequence (underlined
in Figure 4).

However, computer analysis showed that this

additional sequence did not extend the predicted open
reading frame.
3. Primer extension demonstrates heterogeneity of the
transcriptional start site
Primer extension analysis was done to help confirm
that the sequences identified in the RACE clone
represented the 5' terminus of EDl.

A primer that

initiates reverse transcription from position 126 of the
EDl cDNA (Figure 4) was end labeled.

The first strand

cDNA products were resolved on a sequencing gel next to a
ladder of the EDl genomic DNA (isolation and
characterization of the EDl genomic clone is discussed in
section V of the Results) which show the predicted
sequence of the transcript in this region (Figure 6).

A

primer extension product (indicated by the arrow in Figure
6) migrated at the position of the transcription
initiation site as predicted by 5' RACE (Figure 4).

An

additional five primer extension products were detected.
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This figure is representative of results obtained in two
replicate experiments.
Figure 7 summarizes the results of the 5' RACE and
primer extension experiments.

The triangles point to

positions on the genomic DNA sequence that are termini of
the six primer extension products identified in Figure 6.
The arrows indicate the 5' terminal position of 13 clones
isolated by 5' RACE as described above.

The figure shows

that two primer extension products (positions +1 and +8)
align with two distinct 5' termini of the EDl transcripts
as predicted by RACE.

These data strongly suggest a

heterogeneity of transcriptional initiation.

The EDl

promoter was determined to be TATA-less (described in
section V of the Results).

Heterogeneity of

transcriptional initiation is a characteristic that has
been identified with other genes which are controlled by
TATA-less promoters (Kozmik et al., 1992).
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A C G T

Px

FIGURE 6. Primer extension analysis of the EDl
transcriptional start site. cDNA was synthesized from 2
µg of Poly A+ RNA, isolated from L428 cells using an end
labeled primer (the primer sequence is described in
Materials and Methods) that initiates reverse
transcription at position +120. The synthesized products
(lane Px) were resolved on an 8% urea containing
polyacrylamide gel together with the products of a
sequencing reaction of genomic DNA representing the
corresponding nucleotide sequences. The arrow indicates
the position of the predicted transcriptional start site
(position +1 as shown on Figure 4) as determined by . 5 1
RACE.
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RACE

-20

-10
+1
I
I
ggcaaaaccaggcctgacccagccagtcccatcaagcagagaagtagacagcttcagggg

' ' '' ' '
PRIMER EXTENSION

FIGURE 7. Comparison between 5' RACE and primer extension
analysis. Arrows show the positions of the 5' terminal
nucleotides of 13 clones isolated by 5' RACE. Triangles
show the positions of six primer extension products. EDl
sequence containing the transcription initiation regions
was obtained from a Pst I fragment of a genomic clone
which is described in section V of the Results {see figure
22) •
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II. ANALYSIS OF ED1 TRANSCRIPTION BY RT/PCR

A. Analysis of EDl expression in association with the
activation of normal peripheral blood mononuclear cells
The screening protocol used to isolate EDl was
designed to identify genes that may be involved in the
oncogenesis of Hodgkin's disease.

Most tumor associated

genes (or proto-oncogenes) tend to be involved in the
regulation of normal cell growth (Bishop, 1987).
Therefore, I evaluated the novel EDl clone to determine if
it fit the second criteria, that the gene be expressed
during proliferation, not a housekeeping gene.

To do so,

I studied EDl expression in resting and activated
peripheral blood mononuclear cells (PBMC).

Reverse

transcription/polymerase chain reaction (RT/PCR) was used
for this study.
The primers used in the PCR reaction amplify a 326-bp
segment of EDl sequence (between base pair positions 4 and
330 as shown in Figure 4) containing most of the open
reading frame.

In a separated PCR reaction, a 277-bp

segment of the beta-2-microglobulin is amplified from cDNA
as a control to standardize the amount of cDNA added to
the PCR reactions.

Additionally, mock reverse

transcription reactions containing no AMV-RT were done for
each RNA sample tested and amplified to demonstrate that
any detectable product was amplified from a cDNA template.
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In most assays, the PCR reaction mixture was supplemented
with [a32p]-dATP so that the products separated on
agarose gels could be identified by autoradiography.
The time course of EDl expression in activated
lymphoid cells was determined by examining cells
stimulated in culture with phytohemagglutinin (PHA), a
polyclonal T cell mitogen, and collected at various time
points following stimulation.
Figure 8.

The expected 326-bp product was dectected in

L428 cells (lane 2).
(lane 4).

The results are shown in

No EDl was detected in resting PBMCs

Upon activation its expression was detectable

at seven hours following PHA activation (lane 6), but was
not detectable by 24 hours following stimulation (lane 8),
nor was it detected in samples harvested at 48 hours (lane
10) or 72 hours (lane 12) after stimulation.
Amplification of the 277-bp segment of the Beta-2microglobulin gene was of similar intensity for all cDNA
samples to verify that cDNA was synthesized in every
reverse transcription reaction.

No specific products were

amplified from mock cDNA reactions (odd numbered lanes)
verifying that the PCR products detected were specifically
amplified from cDNA synthesized in the reverse
transcription reaction.

This figure is representative of

results obtained in seven replicate experiments.
To determine if the cells were activated by
stimulation with PHA, [3H]-thymidine incorporation was
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FIGURE 8.
Expression of EDl in normal peripheral blood
mononuclear cells (PBMCs) activated with PHA
(phytohemagglutinin). The autoradiograph shows results
using reverse transcription/polymerase chain reaction
(RT/PCR) to measure EDl and Beta-2-microglobulin
transcripts in mRNA isolated from L428 cells (lanes 1 and
2), resting peripheral blood mononuclear cells (lanes 3
and 4), and PBMCs activated with in culture supplemented
with PHA (10 ng/ml) for seven hours (lanes 5 and 6), 24
hours (lanes 7 and 8), 48 hours (lanes 9 and 10) and 72
hours (lanes 11 and 12). The cDNA reactions were done
with (even lanes) and without (control odd lanes) reverse
transcriptase. All reactions were supplemented with 1 µCi
[a32p]-dATP (3000 Ci/mmol) and the products were resolved
by electrophoresis in a 2% agarose gel. Dried gels were
exposed to X-ray film at -85°c.

81

analyzed to measure DNA synthesis.

Stimulated PBMCs

collected at the various time points were seeded at 4 x
105 cells/ml and pulsed for four hours with [3H]thymidine.

The cells were then harvested and [3H]-

thymidine uptake was measured by liquid scintillation
counting.

The results (Table 2) show that the resting

cells and cells stimulated with PHA for seven hours and 24
hours demonstrate background levels of thymidine
incorporation.

However, [3H]-thymidine uptake increases

nearly 40-fold in cells stimulated with PHA for 48 hours.
This was an expected result for cells which are
synthesizing DNA prior to proliferation.

The values shown

in this table are representative of results obtained in
five replicate experiments.

Additionally, cells which

become activated form clumps in culture which are
observable by light microscopy.

Clumping was observed in

cells cultured with PHA for at least 24 hours (data not
shown).

This clumping was not observed in PBMCs cultured

for 24 hours in the absence of stimulus.

These results

strongly suggest that the cells had become activated in
response to the PHA stimulation.
The monoclonal antibody anti-human Leu-4 (anti-CD3)
was next used to specifically activate T lymphocytes.
PBMCs cultured with anti-CD3 were harvested at various
time points and RT/PCR was done as described previously.
The results are shown in Figure 9.

No EDl expression was
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TABLE 2

[3H]-THYMIDINE INCORPORATION

Hours

Mean + SD*
80
211
174
7841
4341

0
7
24
48
72
*n

=

+ 25
+ 143

± 55
± 893

+ 1012

12 for all time
points analyzed

[3H]-Thymidine incorporation values for resting PBMCs and
for PBMCs activated with phytohemagglutinin (PHA).
Cultures harvested at the indicated time points were
pulsed for four hours with 1 µCi [3H]-thymidine per 1 x
105 cells. Levels of [3H]-thymidine were determined by
liquid scintillation counting. Twelve samples were
analyzed for each time point.
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FIGURE 9. Expression of EDl in normal peripheral blood
mononuclear cells activated with anti-CD3 monoclonal
antibody. The autoradiograph shows results using RT/PCR
to measure EDl and Beta-2-microglobulin transcripts in
mRNA isolated from resting peripheral blood mononuclear
cells (lanes 1 and 2), and cells cultured with anti-CD3
for two hours (lanes 3 and 4), four hours (lanes 5 and 6),
six hours (lanes 7 and 8), 12 hours (lanes 9 and 10) and
24 hours (lanes 11 and 12). The cDNA reactions were done
with (even lanes) and without (control odd lanes) reverse
transcriptase. All reactions were supplemented with 1 µCi
(a32p]-dATP (3000 Ci/mmol) and the products were re~olved
by electrophoresis on a 2% agarose gel. Dried gels were
exposed to X-ray film at -a5°c.

84

detected in resting cells (lane 2).

However, EDl was

expressed in cells stimulated with anti-CD3 for two hours
(lane 4), four hours (lane 6) and for six hours (lane 8)
but was no longer detectable by 12 hours (lane 10) nor at
24 hours (lane 12) post activation.

Amplification of the

277-bp segment of the Beta-2-microglobulin gene was of
similar intensity for all cDNA samples.

No specific

products were amplified from mock cDNA reactions (odd
numbered lanes) at detectable levels.

This figure is

representative of results obtained in four replicate
experiments. Cell proliferation was monitored in cells 48
hours after stimulation by (3H]-thymidine incorporation
(data not shown).

A control was done in which

unstimulated cells were cultured for four hours in the
absence of anti-CD3.

The cells were collected, RNA

isolated, and analyzed by RT/PCR.

PBMCs culture for four

hours in the absence of anti-CD3 did not express
detectable levels of EDl (data Rot shown).
To more definitively determine the time that EDl
expression initiates, the experiment was repeated with the
cells harvested within two hours following activation with
anti-CD3.

The data in Figure 10 shows that EDl was not

detectable in resting cells (lane 1), or cells harvested
at either 15 minutes (lane 2) or 30 minutes (lane 3)
following activation with anti-CD3.

However, EDl was

detected in cells one hour following stimulation (lane 4)
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FIGURE 10. Expression of EDl in normal peripheral blood
mononuclear cells activated with anti-CD3. RT/PCR results
of EDl and Beta-2-microglobulin expression in resting
cells (lane 1), and cells incubated in culture with antiCD3 for 15 minutes (lane 2), 30 minutes (lane 3) 60
minutes (lane 4) and 120 minutes (lane 5). All reactions
were supplemented with 1 µCi [a32p]-dATP (3000 Ci/mmol)
and the products were resolved by electrophoresis on a 2%
agarose gel. Dried gels were exposed to X-ray film at

-a5°c.

86

and at two hours following stimulation (lane 5).
Amplification of the 277-bp segment of the Beta-2microglobulin gene was of similar intensity for all cDNA
samples.

No specific products were amplified from mock

cDNA reactions at detectable levels (data not shown).
This figure is representative of results obtained in two
replicate experiments.
A recent classification scheme devised by Gerald
Crabtree has categorized genes which are induced to
expression during T cell activation (Crabtree, 1989;
Altman et al., 1990).

over 100 genes have been identified

that are considered to be T cell activation genes.

These

genes are grouped into three major categories based on
when their expression is initiated following activation;
the immediate early activation genes, which are expressed
within the first 30 minutes following stimulation; the
early activation genes, which are expressed between 30
minutes and 48 hours; and the late genes which are
expressed after 48 hours.

Based on my observations, the

novel clone should be categorized as an early activation
gene and therefore, we named it ELAG (Early Lymphoid
Activation Gene).

B. ELAG Expression in activated Jurkat cells
To help confirm that ELAG (Early Lymphoid Activation
Gene) is expressed in activated T cells, studies were done

87

to evaluate ELAG expression in the Jurkat leukemic T cell
line.

Jurkat cells are an accepted tissue culture line

for studying T cell activation because upon stimulation
with two signals, PHA (phytohemagglutinin) and TPA (12-0tetradecanoyl phorbol-13-acetate), these cells mimic
several responses observed in normal activated T cells
(Gillis and Watson, 1980).

Specifically, activated Jurkat

cells produce and secrete IL-2 in an analogous manner to
normal activated T cells.

Therefore, these studies would

help to confirm the involvement of T cells and provide
information about the signals required for ELAG
expression.

The results in Figure 11 show that ELAG

expression was not detected in Jurkat cells unstimulated
in culture for four hours (lane 1) or 24 hours (lane 5).
ELAG expression was detected in cells cultured for four
hours with either PMA (lane 2) or PHA (lane 3).

Jurkat

cells stimulated with both PHA and PMA for four hours
expressed ELAG (lane 4) at greater levels than were
detected when cells were stimulated with either PMA or PHA
alone.

Jurkat cells cultured with PHA and PMA for 24

hours express barely detectable levels of ELAG (lane 6).
This figure is representative of results obtained in two
replicate experiments.

IL-2 synthesis in resting and

stimulated cells was directly measured by ELISA to
determine if the cells were activated.

The results showed

that unstimulated cells, or cells stimulated with only PHA
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FIGURE 11. RT/PCR analysis of ELAG expression in nonactivated and activated Jurkat cells. ELAG expression in
non-activated and activated Jurkat cells. RT/PCR was used
to measure ELAG and Beta-2-microglobulin expression in the
Jurkat T cell line cultured for four hours in medium alone
(non-activated, lane 1), or medium supplemented with PHA
(lane 2), PMA (lane 3), or PHA and PMA (lane 4), and cells
cultured for 24 hours in medium alone (lane 5) or with
both PHA and PMA (lane 6). All reactions were
supplemented with 1 µCi [a32p]-dATP (3000 Ci/mmol) and the
products were resolved by electrophoresis on a 2% agarose
gel.
Dried gels were exposed to X-ray film at -a5°c.
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or only PMA did not synthesize IL-2.

However, Jurkat

cells stimulated with both PHA and PMA secreted IL-2 into
the culture supernatants (data not shown).

c.

PCR products hybridize with an ELAG specific probe
To determine if the products identified in these

RT/PCR experiments represented ELAG sequences, PCR
products were tested by Southern hybridization.

To do so,

cDNA was added to a PCR reaction and amplified in the
absence of radio-labeled nucleotides.

The products were

separated by agarose gel electrophoresis and transferred
to a nylon membrane.

The membrane was incubated with a

[a32p]-labeled ELAG probe, washed and autoradiographed.
The results in Figure 12 show that amplified products from
L428 cells (lane 2), anti-CD3 activated PBMCs (lane 6),
and PHA/PMA stimulated Jurkat cells (lane 10) hybridized
with a radiolabeled ELAG specific probe.

However, no

hybridization was detected in unstimulated PBMC (lane 4)
or unstimulated Jurkat cells (lane 8).

No specific

products which were amplified from mock cDNA reactions
hybridized with the ELAG probe at detectable levels (odd
numbered lanes).

This figure is representative of results

obtained in three replicate experiments.

These results

confirm that ELAG transcripts are expressed upon
activation of PBMCs or Jurkat cells.
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FIGURE 12. Hybridization of PCR amplified products with
an ELAG specific probe. RT/PCR products from various
cultured cells were separated by electrophoresis through
1% agarose gel, transferred to a nylon membrane and
incubated with either a 32P-labeled ELAG probe or a Beta2-microglobulin probe. The RT/PCR products analyzed were
from L428 cells (lanes 1 and 2), resting PBMCs (lanes 3
and 4), PBMC cultured for four hours with anti-CD3
antibody (lanes 5 and 6), non-activated Jurkat cells
(lanes 7 and 8) and PHA/PMA activated Jurkat cells (lane 9
and 10). The cDNA reactions were done with (even lanes)
and without (control odd lanes) reverse transcriptase.
The membrane was washed and autoradiographed at -as 0 c.
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III. Properties of the putative ELAG-encoded proteins

A.

Amino acid sequence and putative structure of the

ELAG-encoded protein
The predicted amino acid composition of the ELAG open
reading frame shown in Figure 4 was analyzed for consensus
protein motifs and is diagrammed in Figure 13.

Beginning

at the N-terminus, the predicted protein contains the
sequence Pro-Arg-Ala-Lys-Arg (positions 2 through 6) that
is very similar to known nuclear localization signals
(Dingwall and Laskey, 1986).

Also, this terminus is

highly basic and lacks any identifiable signal peptide.
The c-terminus contains a single zinc finger-like motif
that is related to the TFIIIA zinc finger domain
(Cx3Cx12Hx2H; cysteine followed by 3 amino acids, a second
cysteine followed by 12 amino acids, a histidine followed
by 2 amino acids and a final histidine) originally
described in Xenopus (Miller et al., 1985; Brown et al.,
1985).

The computer also identified four potential sites

of phosphorylation.

There are two serine residues

(positions 48 and 65) and one threonine residue (position
102) that are potential substrates of protein kinase-c.
There is also one serine residue (position 9) that is a
potential phosphorylation substrate of c-raf.

This

analysis suggest that the ELAG encodes a nuclear
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FIGURE 13. Structural motifs encoded by the predicted
ELAG-encoded protein. This diagram shows the protein
motifs for the deduced open reading frame based on the
ELAG cDNA sequence (formerly identified as EDl) shown in
Figure 4. R/K putative nuclear localization signal ProArg-Ala-Lys-Arg; s, potential serine sites of
phosphorylation; T, potential sites of threonine
phosphorylation; Cx3Cx12Hx 2H, TFIIIA-like zinc finger
domain.
·
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phosphoprotein utilizing a single zinc finger which
potentially binds DNA or RNA.

B. In vitro translation of the ELAG open reading frame
To investigate the possibility that ELAG utilizes a
CUG translation initiation codon instead of an AUG, I
tested the ability of the ELAG open reading frame to be
translated in vitro from sense transcripts encoding wild
type ELAG sequences versus sense transcripts containing a
mutation at the putative translation start site.

To do

so, I used a PCR based protocol to create the mutation at
the putative translational start site to test the
hypothesis that the CUG (CTG in the cDNA sequence) at
position 55 (see Figure 4) is necessary for translational
initiation.

The mutational process is illustrated in

Figure 14.

Briefly, three PCR reactions are performed

using four different primers.

One pair of primers

(primers B and C) are complementary to each other.

These

primers are identical to the double stranded DNA positions
43 to 67 except that the CTG at position 55 was changed to
TTA on primer

c.

Likewise, the CAG (reverse complimentary

to CTG) was changed to TAA (reverse complimentary to TTA)
on primer D.

In the first two PCR reactions, primers A

and B were used in a single reaction while primers c and D
are used in the other reaction.

The expected products
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Primer Mutagenesis
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PCR with primers A and D
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FIGURE 14. Schematic diagram of the procedure used to
induce mutations in the putative ELAG translational
initiation site. The scheme to mutate the putative CUG
translational start codon to a UUA was done by a two step
PCR amplification. In the first step, two PCR products
are synthesized. One product was amplified between Primer
A and primer c. The other was amplified between primer B
and primer D. Primers B and c encode a two base mismatch
that will be incorporated into the final product. The
products are purified to remove excess primers and added
to the PCR reaction in the second step in which
amplification takes place between primers A and D and
would incorporate the double base mismatch from step 1.
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would overlap and contain the substitutions that allow for
the CTG to TTA change.

The products of each of the

reactions were purified to remove the primers.

The

product are combined in a single PCR reaction and
amplified using primers A and D.

The final

product would contain the sequence change in the full
length clone.

The PCR products were then ligated into the

pGEM™ PCR cloning vector both under control of the T7 RNA
polymerase promoter.

The mutation was designed to alter

the CTG at the putative translational start site to a TTA.
Both CTG and TTA encode leucine so the change will not
affect the peptide sequence.

Sequence analysis of the

mutant and wild type ELAG clones (Figure 15) shows the
mutation at positions 55 and 57 to a T and A respectively.
Sense transcripts from the wild type and mutant cDNA
inserts were synthesized in vitro and analyzed by
electrophoresis through a formaldehyde containing agarose
gel and stained with ethidium bromide to determine the
relative concentration of transcripts produced by each
transcription reaction.

Equal amounts of wild type and

mutant transcripts were added to a wheat germ in vitro
translation system.

The translation products were

separated by SDS-PAGE.

As a control, an in vitro

translation reaction was done in which no RNA was added.
The results in Figure 16 show that a 13-kDa protein was
translated in the reaction supplemented with ELAG sense
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FIGURE 15. The autoradiograph shows the nucleotide
sequence of the wild type ELAG cDNA compared to the cDNA
with the mutated translational start site. The Sanger
sequencing of the subclone mutant PCR fragment is compared
to the wild type sequence. The mutations C to T and G to
A are noted with the symbol C•).
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FIGURE 16. In vitro translation of wild type and mutant
ELAG transcripts. The figure shows an autoradiograph of
an SDS-polyacrylamide gel analyzing wheat germ in vitro
translation reaction containing no RNA (lane 1), in vitro
synthesized transcripts encoding wild type ELAG 3 (lane
2), and in vitro synthesized transcripts encoding ELAG 3
in which the CUG start codon was mutated to a UAA (lane
3) •
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RNA (lane 2) that was not present in the mock translation
(lane 1).

This data is consistent with computer analysis

of the ELAG open reading frame which predicts that ELAG
encodes a 13.2-kDa protein.

The translation reactions

that received the mutant transcript (lane 3) shows no
detectable levels of a 13.2-kDa protein.

This figure is

representative of results obtained in three replicate
experiments.

The data shows that the ELAG-encoded open

reading frame, without an in-frame AUG, can be translated.
Additionally, by altering the CUG at sequence position 55
reduces the translational efficiency to undetectable
levels, thus indicating that the CUG is the utilized
translational initiation site for ELAG-enocded protein.
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IV.

Characterization of the transformation potential of

ELAG

A. Rationale
The results described in the previous section
demonstrate that ELAG is expressed in association with
normal lymphoid cell growth and proliferation.

This is a

characteristic common to the proto-oncogenes in that they
are normally involved in the regulation of cell growth and
proliferation (Bishop, 1987).

Therefore, ELAG is a

candidate gene, like a proto-oncogene, such that when
perturbed could be involved in the transformed phenotype.
Proto-oncogenes become involved in the development of the
transformed phenotype by two major mechanisms: 1) mutation
which alters the open reading frame and subsequently
changes the structure and activity of the protein, or 2)
the proto-oncogene becomes over-expressed (Bishop, 1987).
I was interested in determining if either alteration
potentially affects ELAG in Hodgkin's-disease cells or
other tumor types.

B. Analysis of potential mutations associated with ELAG
expressed in the Hodgkin's disease L428 cells
In order to identify any potential tumor specific
mutations in ELAG, it was necessary to obtain and sequence
cDNA clones from normal activated PBMCs and compare them
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with the sequences of the L428 derived clones.

Clones

were isolated from activated PBMCs using 3' RACE (Rapid
Amplification of cDNA Ends) as illustrated in Figure 17.
Poly A+ RNA isolated from anti-CD3 activated PBMCs and
used as a template in a cDNA reaction.

Synthesis of cDNA

was initiated by priming with a modified poly(dT) primer
(described in Materials and Methods) that has a
specifically engineered tail at the 5' terminus.

The cDNA

was amplified in a PCR reaction containing a modified
ELAG-specif ic primer (ELAG sequences are identical to
positions 64 through 85 shown on Figure 18; this primer
has a modified tail that allows for rapid cloning into the
pAMP-1™ vector which is described in the Materials and
Methods section), and a primer which is reverse
complementary to the tail on the modified poly(dT) primer
(described in Materials and Methods).

The RACE products

were subcloned into pAMP-1™ using procedures described in
the Materials and Methods.

The clones were isolated by

hybridization using a [32p]-labeled ELAG specific probe.
Clones isolated by this method were sequenced in both
directions and are shown in Figure 18 (positions 64 to
667).

Surprisingly, this new clone contained sequences

not encoded by the EDl-ELAG clone shown in Figure 4.

In

order to characterize the entire clone, 5' RACE was done
(described previously as shown in Figure 5) using a primer
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3' RACE

l
l
l

AAAAAAA
Step 1

AAAAAAA
TTTTTTT
Step 2

TTTTTTT
Step 3

AAAAAAA
TTTTTTT

FIGURE 17. Schematic diagram of the 3 1 RACE procedure
used to isolate ELAG clones from normal activated PBMCs
and L428 cells. Reverse transcription of RNA isolated
from either L428 cells or PBMCs activated in culture for
four hours with anti-CD3 monoclonal antibody was initiated
with oligo(dT). The cDNA was amplified using a poly(dA)
primer and primer 1 which is identical to the coding
strand of the ELAG and positioned near the amino terminus
of the open reading frame. The PCR products are subcloned
and sequenced as described in Materials and Methods.

102

20

10

30

40

50

60

AGT CCC ATC AAG CAG AGA AGT AGA CAG CTT CAG GGG AGG CAG GGG TGA GCA GAG CTG CCA
AGT CCC ATC AAG CAG AGA AGT AGA CAG CTT CAG GGG AGG CAG GGG TGA GCA GAG CTG CCA

80

70

90

100

110

120

AGA GCA AAA AGA AAC CAT TCA TAT CAC CTT AGA TAC CAC GGC TCT TCC TAC TCC AGG TGC
AGA GCA AAA AGA AAC CAT TCA TAT CAC CTT AGA TAC CAC GGC TCT TCC TAC TCC AGG TGC

130

140

150

160

170

200

210

220

230

260

270

280

290

320

330

340

350

380

390

400

410

440

450

460

470

500

510

520

530

560

570

580

590

620

630

640

650

Normal

Hodgkin's

Normal
Hodgkin's

Normal
Hodgkin's

Normal
Hodgkin's

600°

ACA TCA TTG GAA CAT GGA TGG TTG ATT AGA TGG AAG TAT TAC ATT AAT GAT ACA TTT TCC
ACA TCA TTG GAA CAT GGA TGG TTG ATT AGA TGG AAG TAT TAC ATT AAT GAT ACA TTT TCC

610

Hodgkin's

540

TCT GGA CTG GAT CTT GCA TTG GAG GAG AAA ATG CTA TAA AAG GTA TCA CTG AGA CAG TTA
TCT GGA CTG GAT CTT GCA TTG GAG GAG AAA ATG CTA TAA AAG GTA TCA CTG AGA CAG TTA

550

Normal

480

AGG AAC TGT TCC ACA TTA AAG GAG ACT AAG AAG ACA TAA CAA CTC GAT GCA ATG TGT GAT
AGG AAC TGT TCC ACA TTA AAG GAG ACT AAG AAG ACA TAA CAA CTC GAT GCA ATG TGT GAT

490

Hodgkin's

420

GAA AAA AAA TGA AAG AAG ATT GTG AGA CTG CCA GAA TTC TAC AGT GTA TGC AAT GGT ATG
GAA AAA AAA TGA AAG AAG ATT GTG AGA CTG CCA GAA TTC TAC AGT GTA TGC AAT GGT ATG

430

Normal

360

TTT TTG AGA ATG TTC TAC CAT CAG AAA CAC TTC CAA CTG GGC CTA AAA GGG ACA GAG ACA
TTT TTG AGA ATG TTC TAC CAT CAG AAA CAC TTC CAA CTG GGC CTA AAA GGG ACA GAG ACA

370

Normal

Hodgkin's

300

GTG AGG ACC CTC TTT TCT GAA TGT GTG AAT CAA TGT GAC ATA CGT AGA AGA CCC ACA AGA
GTG AGG ACC CTC TTT TCT GAA TGT GTG AAT CAA TGT GAC ATA CGT AGA AGA CCC ACA AGA

310

Hodgkin's

240

TGT CTT GAA ACG CGA TCA GAA AAA GCC AAG AAT AGA GAT GGG GTT GTT CAG GAA AAA TCT
TGT CTT GAA ACG CGA TCA GAA AAA GCC AAG AAT AGA GAT GGG GTT GTT CAG GAA AAA TCT

250

Normal

180

TTC CTG GAG AGG TAT AGA TGC AAA ACT ATA GGA GTC TTT AGA AGA AGC AAC CAG CCG GAC
TTC CTG GAG AGG TAT AGA TGC AAA ACT ATA GGA GTC TTT AGA AGA AGC AAC CAG CCG GAC

190

Normal
Hodglun•s

Normal

Hodgkin's

660

TGA ATT TGG TAA CTT TGC TAT TGT TAC CTA CAC GAA TAC TCT GCT CTA GGA AAC AGT AAT
TGA ATT TGG TAA CTT TGC TAT TGT TAC CTA CAC GAA TAC TCT GCT CTA GGA AAC AGT AAT

Normal
Hodgkin's

665
GA~

Normal

GA

Hodgkin's

FIGURE 18 . Compar·ison of the complete nucleotide
sequences of the ELAG-related cDNA clone isolated from
activated PBMCs (Normal) versus the ELAG-related clone
isolated from L428 cells (Hodgkin's).
5' RACE and 3' RACE
clones were isolated using mRNA from L428 cells or from
PBMCs collected four hours after activation with anti-CD3.
The sequences underlined indicate the only region of
divergence between the two cDNA clones.
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(reverse/complementary to sequences at positions 488
through 505 on Figure 18) to initiate reverse
transcription.

The poly(dG) tailed cDNA products were

amplified as using a modified poly(dC) primer and a
modified primer specific to the ELAG-related clone
(reverse complementary to positions 462 through 481 as
shown on Figure 18; this primer has a modified tail that
allows for rapid cloning into the pAMP-1™ vector which is
described in the Materials and Methods section).

The

sequences obtained from this analysis showed that the 5'
terminus of the ELAG-related clone was identical to the 5'
terminus of the EDl-ELAG cDNA shown in Figure 4.
Since my original objective in this study was to
search for mutations in the L428 associated clone, it was
necessary to repeat the 5 1 and 3' RACE procedure using RNA
isolated from L428 cells in an effort to isolate a clone
similar to ELAG-related clone from activated PBMCs.

Such

a clone was isolated from L428 cells and sequenced.

A

comparison of the ELAG clone isolated from normal
activated PBMCs versus the Hodgkin's-disease L428 tumor
cell line is shown in Figure 18.

The results show that

the sequences of the ELAG-related clone are nearly
identical.
terminus.

The only differences identified are at the 3'
The cDNA clone isolated from normal activated

PBMCs has an additional five base pairs (underlined in
Figure 18) not identified on the tumor associated ELAG
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clone.

It is possible that these differences are the

result of a cloning artifact and do not represent actual
differences in the sequences of the transcripts.

No

sequence divergence was detected in the computer predicted
open reading frame.

Therefore, the ELAG-related clones

isolated from activated PBMCs and L428 cells would encode
the same protein.

c.

ELAG family members from L428 cells
To date, four distinct but related clones have been

isolated by the RACE and rescreening the library.

These

clones have all been sequenced and comparison is shown in
Figure 19.

The EDl-ELAG clone originally isolated from

the Hodgkin's disease L428 cell line by differential
screening (Figure 4) is now designated as ELAG 1.
and ELAG 2
library.

ELAG 1

were isolated only from the L428 Lambda ZAP™
The ELAG-related clone isolated from activated

PBMCs and L428 cells (Figure 18) is now designated as ELAG
3.

ELAG 3 was only isolated by RACE.

ELAG 4 was isolated

from both the cDNA library and by RACE.
Eight regions of sequence identity (regions A through
H) have been identified (Figure 19).

All segments

represented by a given letter share 100% sequence
identity.

All clones identified to date encode region A.

ELAG clones 1, 2, and 3 contain region B.

Region

c

is

unique to ELAG 1, while regions D and G are unique to ELAG
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c

ELAG 1

A

B

ELAG 2

A

B

D

ELAG 3

A

B

E

ELAG 4

A

E

E

F

G

H

F

FIGURE 19. Comparison of the sequences of the four ELAG
cDNA clones isolated from the L428 cell line. The
sequence identity shared by each clone is displayed with a
letter. The 13.2-kDa open reading frame is encoded in
regions A and B.
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2 and region H is unique to ELAG 3.

No unique regions

were identified in ELAG 4.
The open reading frame identified by computer
analysis in ELAG 1 (Figure 4) is encoded in regions A and
B.

Therefore, ELAG clones 1, 2, and 3 all contain the

same open reading frame, but have different 3' termini.
ELAG 4 has an open reading frame that is terminated
shortly after region A.

Interestingly, the open reading

frame contained in region B encodes a zinc finger motif,
and therefore ELAG 4 protein would not exhibit this
domain.
Northern blot analysis was done using restriction
fragments of ELAG clones as probes to dispel any
possibility that the ELAG members were cloning artifacts.
Figure 20A shows a partial restriction enzyme digestion
map of the ELAG clones used to prepare probes for this
study.

Three probes were used: 1) a 340-bp EcoR I

fragment of the ELAG 1 clone which contains regions A and
B and therefore is expected to hybridize to all ELAG
transcripts, 2) a 668-bp BamH I fragment of ELAG 1 which
contains only region C and therefore should be specific
for ELAG 1, and 3) a 1.0-kb EcoR I fragment of ELAG 2
which contains regions D, E, F and G and therefore is
expected to hybridize to ELAG 2, ELAG 3 and ELAG 4
transcripts.
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A
ELAG 1

A

B

ELAG 2

A

B

c

....
D
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·-··

E

F

G

B
1

2

J

- ?BS
l

I
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I

-

s

FIGURE 20. Northern blot analysis of RNA isolated from
L428 cells using restriction fragments of ELAG cDNA clones
as probes. Panel A show partial restriction maps of ELAG
1 and ELAG 2. Panel B shows the autoradiographs of RNA
hybridized with the following probes: lane 1, a 340-bp
EcoR I fragment of ELAG 1 containing regions A (common to
all ELAG clones identified to date) and B; lane 2, a 668bp BamH I fragment of ELAG 1 containing the 3' terminal
portion of the region C which is ELAG 1 specific; and lane
3, a 1.1-kb EcoR I fragment of ELAG 2 which contains
regions D, E, F and G.
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RNA from L428 cells was separated by electrophoresis
through a formaldehyde containing agarose gel in three
replicate lanes, transferred to nylon membrane, incubated
with [32p]-labeled probes, and autoradiographed.

The

results of the hybridization study are shown in Figure
20B.

A probe containing sequences from regions A (common

to all clones identified) and B (common to ELAG 1, 2, and
3) hybridized to two major transcripts, 1.8-kb and 1.3-kb,
and two minor transcripts, 1.1-kb and 0.9-kb (lane 1).

A

probe specific for ELAG 1, hybridized only to the upper,
1.8-kb transcript (lane 2).

The 1.0-kb EcoR I fragment of

ELAG 2, which contains regions D, E, F, and G hybridized
to the 1.3-kb transcript (lane 3).

Hybridization with the

1.1-kb and the 0.9-kb transcripts are barely detectable.

D. Analysis of ELAG expression in human tumor cell lines
Since ELAG expression is regulated during T cell
activation, it is a candidate gene that when
constitutively expressed or over-expressed may affect the
cellular phenotype.

To test the third criteria that I

established for evaluating clones isolated by differential
screening, I wanted to determine if ELAG is aberrantly
expressed in association with the development of the
transformed phenotype.

To do so, several tumor cell lines

were tested for ELAG expression by RT/PCR.

The data in

Figure 21 show that the Hodgkin's-disease cell line L428
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FIGURE 21. Expression of ELAG in human cell lines.
RT/PCR results of ELAG and Beta-2-microglobulin expression
in L428 Hodgkin's-disease cells (lanes 1 and 2), EBVinfected African Burkitt•s lymphoma lines Jiyoye (lanes 3.
and 4), P3HR-1 (lanes 5 and 6), and Raji (lanes 7 and 8),
the T cell line HuT 78 (lanes 9 and 10) and the normal
human fibroblast lin IMR-90 (lanes 11 and 12). cDNA
reactions were done with (even lanes) or without (odd
lanes) reverse transcriptase. All reactions were
supplemented with 1 µCi [a32p]-dATP (3000 Ci/mmol) and the
products were resolved by electrophoresis on a 2% agarose
gel.
Dried gels were exposed to X-ray film at -85°~.
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express the highest levels of ELAG (lane 2), while Jiyoye
cells express small but detectable amounts of ELAG (lane
4).

The P3HR-1 cell line did not express detectable

levels of ELAG.

I predicted this expression profile given

that the ELAG clone was isolated through a differential
screening method which targeted genes that are expressed
in L428 and Jiyoye cells but not in PJHR-1 cells
(described in section I of the Results).

Several other

cell lines tested do not express detectable levels of ELAG
including the EBV infected African Burkitt's lymphoma cell
line, Raji (lane 8); the T cell lymphoma line, HuT 78
(lane 10); and the normal lung fibroblast line, IMR-90
(lane 12).

This figure is representative of results

obtained in four replicate experiments.

These results

show the restricted nature of ELAG expression in tumor
cell lines.

Additionally as shown in Figures 11 and 12,

ELAG is not expressed in unstimulated Jurkat T cell
leukemic line.

Further, ELAG expression was not detected

in resting PBMC (Figures 8, 9, 10, and 12).

Taken

together, these results suggest that ELAG is
constitutively expressed only in the Hodgkin's-disease
cell line L428 and to a lesser degree in the EBV infected
African Burkitt's lymphoma cell line Jiyoye.
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v.

Transcriptional control of ELAG

To understand how aberrant signal could potentially
affect ELAG expression in Hodgkin's-disease cells and to
understand the molecular basis of the transient expression
of ELAG in activated T cells, it was necessary to
investigate the signals involved in the regulation of ELAG
transcription.

To do so, I isolated clones from a WI 38

human lung fibroblast genomic library and sequenced the
transcriptional control region.

The library was screened

using probes containing ELAG sequence regions A and B (see
Figures 19 and 20A).

Two overlapping clones, designated

6-3 and 6-4 (Figure 22), were isolated.
contains regions B and c of ELAG 1.

Clone 6-3

Clone 6-4 contains

region A of ELAG 1 plus the transcriptional control
region.

A 4.5-kb Pst I fragment of the 6-4 clone was

ligated into pBluescript™ and sequenced upstream to
position -135, with respect to the designated
transcriptional initiation site, using ELAG specific
primers.

The sequences surrounding the putative

transcriptional start site, indicated with an arrow at
position +1, are shown in Figure 23.

This transcriptional

start site was identified by primer extension and 5 1 RACE
(Figures 6 and 7).
No TATA-like element was identified near the expected
position of -30 from the transcriptional start site.
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FIGURE 22. Partial restriction map of the overlapping ELAG
clones 6-3 and 6-4 which were isolated from the WI-38
human lung fibroblast genomic library. H, Hind III; s,
Sac I.
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-116
-126
-106
-96
-86
-76
*
*
*
*
AGAGCTCACA GTCCGCTTTG ATGAAA,TTCC ATGTTTCTTA CTTGAAAGGG CTGYACCCAT
CD28 RB

-66
-56
-46
-36
-26
-16
*
*
*
*
*
*
GATTAGGACT TCCTCCTCTT GATCAGTGAC TCAGACCTGA GICAGTCAGA AAGCAAAACC
'l'U:

'l'RE

-6
15
25
35
45
*
*
*
*
AGGCCTGACC CAGCCAGTCC CATCAAGCAG AGAAGTAGAC AGCTTCAGGG GAGGCAGGGG

-

INR

FIGURE 23. Nucleotide sequence of the putative
transcriptional control region of the ELAG 1 gene isolated
from the genomic library derived from the WI-38 human lung
fibroblast cell line. A map of the 135 base pairs
immediately 5 1 of the proposed ELAG transcriptional start
site (arrow) contains the INR at position -11 to +4, two
tandem TPA response elements (TRE) and a consensus CD28
receptor element (CD28 RE) binding site.
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However, sequences surrounding the transcriptional start
sited share 80% identity with the initiator region (INR)
originally identified in the murine terminal
deoxynucleotidyl transferase (TdT) gene (Smale and
Baltimore, 1989; Smale et al., 1990).

Previous studies

have shown that an INR can independently initiate
transcription (Smale et al., 1990), therefore, a promoter
containing this element does not require a TATA-box.

The

putative INR at position -11 through +4 likely allows for
transcriptional initiation from the adenosine at position
+1.

However, the primer extension analysis data shows a

heterogeneity of transcriptional initiation (Figures 6 and
7).

Multiple transcriptional start sites have been

described for other genes controlled by TATA-less
promoters (Kozmik et al., 1992).
Two TPA response elements (TRE) are aligned at
positions -37 and -53 with respect to the transcriptional
start site (Holbrook and Fornace, 1993; Angel and Karin,
1991).

A consensus CD28 receptor element (Fraser et al.,

1991) (CD28 RE) binding site was identified at position
-110.

DISCUSSION

Isolation of ELAG: A potential cellular target of EBV
immortalization
The novel ELAG (early lymphoid activation gene) cDNA
clone was isolated utilizing a differential screening
protocol designed to identify genes that are expressed in
association with lymphoid cell growth and in the
transformation of cells to the Hodgkin's disease
phenotype, as well as Epstein-Barr virus (EBV) infected
Burkitt's lymphoma.

The rationale for this study was

based on the recent studies demonstrating by in situ
hybridization that the EBV genome is harbored in the ReedSternberg cells of diseased tissue in 25-60% of the
Hodgkin's disease patients tested (Anagnostopoulos et al.,
1989; Weiss et al., 1989; Staal et al., 1989; Libetta et
al., 1990).

These studies supported a long held

speculation that EBV may be a causative agent of Hodgkin's
disease.

I hypothesized that the oncogenic events

responsible for Hodgkin's disease, both EBV associated and
EBV negative independent Hodgkin's disease, are mediated
by aberrant expression of cellular genes which are also
aberrantly expressed in EBV infected non-Hodgkin's
lymphoma.

My objective was to identify genes involved in
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this putative pathway in order to elucidate the signal
transduction pathway and biochemical alterations
responsible for transformation of cells to the Hodgkin's
disease phenotype.
I developed a differential screening procedure (shown
in Figure 1) designed to identify genes expressed in
association with Hodgkin's disease and that may be
cellular targets of the EBV encoded immortalization
factor, EBNA 2 (Cohen et al., 1989; Cohen et al., 1992).
Clones isolated by this method were tested to determine if
they meet three criteria.
novel genes.

First, I was interested in

One gene of interest was the CD30 gene which

is expressed following EBV induced immortalization and its
expression is associated with Hodgkin's disease.

At the

time of the screening, the CD30 gene had not been
isolated.

Second, I was interested in clones that are

expressed in association with Hodgkin's disease and EBV
mediated transformation.

Third, I was interested in

clones which are expressed in association with normal
lymphoid cells growth, not housekeeping genes.

I was

interested in such genes because most tumor associated
genes (or proto-oncogenes) tend to be involved in the
regulation of normal cell growth.
Several clones isolated by the differential screening
procedure were sequenced to determine if they met the
first criteria (Figures 2 and 3).

This study showed that
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only one clone demonstrated very low levels of relatedness
to any sequences in the GenBank/EMBL data bases (Figure
3), signifying that the clone is likely novel (i.e.
previously not described).
Expression of the novel clone was detected in the EBV
negative L428 Hodgkin's-disease cell line and in the EBV
infected Jiyoye African Burkitt•s cell line (Figure 21).
These results are consistent with the involvement of ELAG
in Hodgkin's disease and Burkitt•s lymphoma.
Additionally, ELAG was not expressed at detectable levels
in the P3HR-1 African Burkitt•s lymphoma cell line.

This

was expected in that clones isolated by differential
screening were selected based on their expression in
Jiyoye but not P3HR-1 cells.

Jiyoye cells are infected

with a viral strain containing EBNA 2, and the phenotype
of these cells as indicated by the expression of cell
surf ace proteins suggest that EBNA 2 has induced the
expression of cellular genes associated with EBV mediated
immortalization.

P3HR-1 cells, on the other hand, are

infected with and EBNA 2 negative, non-immortalizing
strain of EBV.

The cellular environment in which ELAG is

expressed indicates that it is a potential target of EBNA
2, either directly or indirectly.

EBNA 2 is a

transactivator of cellular genes including CD23 (Wang et

al., 1990; Wang et al., 1987).

It would be interesting to
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determine if cis elements in the transcriptional control
region of ELAG are substrates of EBNA 2 activity.

The role of ELAG in normal T cell activation
A third criteria that I established to determine if
clones isolated by differential screening were suitable
for additional study was that they should be expressed in
association with normal cell growth and proliferation.

I

was interested in identifying genes which could
potentially be involved in the development of the
transformed phenotype of Hodgkin's disease.
Transformation associated genes {i.e. proto-oncogenes)
tend to function normally in the regulation of cell growth
and proliferation {Bishop, 1987).

Therefore, if ELAG is

involved in the oncogenesis of Hodgkin's disease, it would
likely be involved in the regulation of normal cell
growth.

During a study designed to determine the role of

ELAG in normal cell growth I demonstrated that the novel
clone is expressed in association with the activation of T
lymphocytes in a population of peripheral blood
mononuclear cells {PBMC; Figures 8, 9, 10 and 12).
The novel ELAG gene is expressed within one hour
following activation of PBMC with anti-CD3 monoclonal
antibody {Figure 10).

This antibody specifically

stimulates T cell activation by binding to the T cell
receptor/CD3 molecule, also known as the antigen receptor

119

complex.

These data strongly suggest that ELAG is

expressed in activated T cells of the PBMC population.

To

help confirm this observation, ELAG expression was studied
in Jurkat human leukemic cell line which is an accepted
tissue culture model for the investigation of events
during T cell activation.

Jurkat cells can be stimulated

to produce IL-2 by mechanisms that are analogous to those
in activated T cells (Gillis and Watson, 1980).
Activation of Jurkat cells requires two signals,
stimulation of the TCR/CD3 complex coupled with induced
activation of protein kinase c (Gillis and Watson, 1980).
In tissue culture, these signals can be provided by the
addition of PHA (phytohemagglutinin) and PMA (phorbol 12myristate 13-acetate, also known as TPA).

I found that in

vitro activation of Jurkat cells with PMA and PHA will
induce ELAG expression in four hours (Figure 11).

These

data are consistent with the designation of ELAG as a T
cell activation gene.

Furthermore, either of these two

signals added in culture individually is sufficient to
induce ELAG expression.

In contrast, expression of IL-2

requires two signals; both PHA and PMA (Gillis and Watson,
1980).

These data indicated the biochemical signals

required for induction of ELAG expression are less complex
than the signals required for stimulation of IL-2
production.

Additionally, the AP-1 transcription factor

is activated by stimulation with PMA (Holbrook and
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Fornace, 1993; Angel and Karin, 1991).

Induction of ELAG

expression with PMA alone further supports the argument
that ELAG is an immediate downstream target of AP-1
transcriptional activator.
T cell activation is very complex and is poorly
understood.

More than 100 different genes and proteins

have been identified that are expressed during T cell
activation (Crabtree, 1989; Altman et al., 1990), and
their expression is activated in a coordinated manner that
is tightly regulated (Altman et al., 1990; Ullman et al.,
1990; Furue et al., 1990).

The complexity of this cascade

of genes is highlighted by the recent studies of Zipfel et
al. who have isolated 60 novel cDNA clones, by subtractive

screening, which are expressed following T cell activation
(Zipfel et al., 1990; Irving et al., 1989).

These

investigations support the contention that there are many
signals involved in T cell activation that are not
understood.

Because ELAG is expressed in activated T

cells, further study of its properties may provide
additional information about the molecular events required
in the immune response and in general in lymphoid cell
growth and proliferation.
Crabtree has categorized the cascade of genes
expressed during T cell activation into three major groups
(Crabtree, 1989; Ullman et al., 1990); immediate early
activation genes, early activation genes and late
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activation genes.

Immediate early genes are expressed in

the first 30 minutes following activation and include cfos (Distel and Spiegelman, 1990; Grausz et al., 1986;

Moore et al., 1986; Gonda and Metcalf, 1984), c-myc (Reed
et al., 1986; Grausz et al., 1986; Moore et al., 1986;

Reed et al., 1985; Gonda and Metcalf, 1984), and NF-KB
(Jamieson et al., 1991).

These genes generally are

involved in transcriptional activation.

The second group

of genes expressed between thirty minutes and forty-eight
hours are known as the early activation genes.

Genes

expressed after 48 hours are called the late activation
genes.
Based on my studies, ELAG is best categorized as an
early antigen, induced to expression by stimulation with
anti-CDJ antibody within one hour but is no longer
detectable by twelve hours post-activation (Figures 9 and
10).

Included in the group of early activation genes are

the IL-2 receptor (Wakasugi et al., 1985; Leonard et al.,
1984; Nikaido et al., 1984), IL-2 and other interleukins
(Norma, 1986; Kinashi et al., 1986; Hirano et al., 1986),
and c-myb (Reed et al., 1986; Stern and Smith, 1986;
Torelli et al., 1985; Torelli et al., 1985; Thompson et
al., 1986).

The early genes are heterogeneous in their

function and are expressed prior to DNA synthesis.
Therefore, they probably act as mediators between the
immediate early genes and the signals that actually induce
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DNA synthesis and cell division (Altman et al., 1990).
Analysis of the transcriptional control region of ELAG
shows that it contains two TPA Response Elements (TRE;
Figure 23).

The TRE is a consensus binding site for the

AP-1 transcription factor.
of Jun and Fos proteins.

AP-1 factor is a heteroduplex
Expression of Fos is sharply

increased during T cell activation (Distel and Spiegelman,
1990; Grausz et al., 1986; Moore et al., 1986; Gonda and
Metcalf, 1984) prior to the expression of ELAG.

The

presence of TRE elements in the ELAG promoter region, and
the temporal relationship between the expression of ELAG
and Fos strongly suggest that ELAG is an immediate
downstream substrate for the AP-1 factor.

The effect of

AP-1 activity during T cell activation is poorly
understood because, to date, very few genes expressed
during T cell activation have been shown to contain a TRE.
However, it is thought that AP-1 is a critical nuclear
factor required to induce expression of other cellular
genes that are necessary to regulate the T cell activation
cascade.
The molecular response required to commit to the
activation cascade is made between 30 minutes and 2 hours.
The signals required for this event are poorly understood.
ELAG is expressed in a time that might allow it to provide
an important signal required for the T cell to commit to
the activation pathway.

Additionally, ELAG is expressed
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during a period when the activated T cell advances from Go
to G1 in the cell cycle.

IL-2, which is expressed between

1 and 24 hours following T cell activation, has been shown
to be essential for inducing the T cells to enter cell
division.

Similar signal requirements and similar

temporal expression indicate that ELAG may also be
directly involved in lymphoid cell proliferation.

ELAG potentially encodes a nuclear phosphoprotein
To better understand how ELAG might function during T
cell activation and possibly in the regulation of cellular
proliferation, I analyzed the predicted open reading frame
to identify structural motifs.
I have shown by in vitro translation that the
translation of a 13.2-kDa protein is initiated from a CUG
translational start site (Figure 16).

Very few eukaryotic

genes identified encode non-AUG start sites but the
examples are well documented.

The concept that all

mammalian cellular proteins were translated from an AUG
initiation codon was dispelled when Pirastu et al. showed
that a human alpha-globin gene containing a mutated start
codon still allowed for the production of a protein;
although this mutation is associated with a clinical
thalassemia (Pirastu et al., 1984).

This finding

demonstrated that the cells translational machinery could
recognize a non-AUG translational initiation site.

Since
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then, several normal genes have been identified which
encode proteins that initiate from non-AUG codons
including the Drosophila encoded choline acetyltransferase
(Sugihara et al., 1990), viral encoded genes including the
murine leukemia virus gp85gag (Prats et al., 1989), equine
infectious anemia virus Tat and Rev proteins (Stephens et
al., 1990), and the parainfluenza virus C' protein (Prats
et al., 1989).

Several human genes utilize non-AUG

translational initiation sites and include basic
fibroblast growth factor (Prats et al., 1998; Clements et
al., 1988), choline acetyltransferase (Strauss et al.,

1991), c-myc (Hann et al., 1992; Hann et al., 1988), int-2
(Acland et al., 1990), TEF-1 (Xiao et al., 1991), Itk
(Bernards and de la Monte, 1990), Hck (Lock et al., 1991),
Krox-24 (Lemaire et al., 1990), and Trk (Martin-Zanca et
al., 1989).

The role of non-AUG translational initiation sites is
unclear; however, recent investigations have shown that
multiple isoforms of int-2 which are translated from the
same gene are localized to different sub-cellular
compartments (Acland et al., 1990).

Additionally, Prats

et al. suspect that the use of a non-AUG start site may be

a post-transcriptional control mechanism {Prats et al.,
1998).
Computer analysis predicts the presence of an amino
acid motif beginning at position 2 (Figure 13), Pro-Arg-
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Ala-Lys-Arg, that is similar to nuclear localization
signal (NLS) motifs identified in known nuclear factors
(Dingwall and Laskey, 1986).

This property suggests that

ELAG is likely to function in the nucleus.
An NLS is the minimum amino acid sequence required to
transport protein to or retain protein in the nucleus.
The best characterized NLS is encoded by the SV40 large T
antigen.

The minimum sequence of amino acids required for

localization of T-antigen in the nucleus is Pro-Lys-LysLys-Arg-Lys-Val (Lanford and Butel, 1984; Kalderon et al.,
1984; Kalderon et al., 1984).

Since the identification of

this motif, similar, yet non-identical, signals have been
identified in other proteins (Dingwall and Laskey, 1986).
The function of the individual amino acids in the NLS is
unclear, but they are probably important in recognition by
chaperone proteins.
The NLS is likely to be involved in the
transportation of large proteins into the nucleus.
Proteins greater than sixty kilodaltons (kDa) are excluded
from diffusing through the nuclear pore where small
proteins freely diffuse (Paine, 1975).

However, smaller

proteins diffuse out at the same rate in which they
diffuse into the nucleus.

Therefore, they must be

selectively retained (Feldherr and Ogburn, 1980; Merriam
and Hill, 1976).

It is likely that the NLS serves this

purpose for proteins smaller than 60-kDa.

Since ELAG is
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only 13.2-kDa, the putative NLS may be important for
retaining the protein in the nucleus.
Also identified in the predicted amino acid sequence
is a Cx3Cx12Hx2H (cysteine followed by 3 amino acids,
another cysteine followed by 12 amino acids, a histidine
followed by 2 amino acids and a final histidine) motif
similar to the tandemly-repeated pattern identified in the
amino acid sequence of the Xenopus TFIIIA zinc finger
protein (Figure 13) (Miller et al., 1985; Brown et al.,
1985).

Zinc fingers are protein domains that fold

producing an alpha helical structure which binds a zinc
ion.
Hundreds of genes identified encode a zinc fingerlike motif similar to the zinc finger motifs of the TFIIIA
transcription factor (Miller et al., 1985; Brown et al.,
1985; Klevit, 1991).

The function for most of these

putative zinc finger containing proteins in many cases is
not known.

However, several proteins definitively shown

to encode a zinc finger domain are well characterized and
serve important regulatory functions including the
regulation of gene expression including growth signals
EGRl (Early Growth Response gene 1) (Sukhatme et al., 1988)
and EGR2 (Early Growth Response gene 2) (Joseph et al.,
1988), Drosophila segmentation genes Hunchback (Tautz et
al., 1987), and Kruppel (Rosenberg et al., 1986).

In

addition to these examples, several recently identified
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genes involved in T cell development and activation encode
zinc finger proteins including Ikaros (Georgopoulos et

al., 1992) and pAT133 (Muller et al., 1991).
Zinc finger containing proteins have been primarily
identified as transcriptional regulators due to their
specificity for binding target DNA in the promoter region
of certain genes.

Known transcriptional factors that

utilize the zinc finger structure which directly interact
with DNA include TFIID and ZIF268.

These proteins

interact with different cis elements showing that all zinc
fingers are not alike.

However, some studies show that

the zinc finger region binding to DNA requires two
guanosine residues with the appropriate spacing (Pavletich
and Pabo, 1991).

The finger motif binds in the large

groove of the target DNA sequence (Pavletich and Pabo,
1991).

Most zinc finger encoding proteins contain

multiple finger motifs, however, only a single zinc finger
domain is required for DNA binding (Baldarelli et al.,
1988; Lee et al., 1989; Parrage et al., 1988)
Zinc finger domains have functions other than
transcriptional regulation through DNA binding.

TFIIIA

from Xenopus has been shown to bind to both RNA and DNA
(Darby and Joho, 1992; Clemens et al., 1993).

Recently

Gottesfeld et al. molecularly dissected the TFIIIA
protein, which encodes nine zinc finger domains, to
determine which domains were essential for DNA binding and
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those essential for RNA binding.

Their results

demonstrate that some zinc fingers were only involved in
RNA binding while the others were involved with DNA
binding (Clemens et al., 1993).

However, they were unable

to identify any properties such as a consensus sequence
which would distinguish a DNA-binding zinc finger domain
from an RNA-binding zinc finger domain.
Other evidence suggests that zinc fingers may be
involved in protein-protein interactions.

The DNA binding

domain of the estrogen receptor encodes two zinc fingerlike motifs; one has DNA binding capacity, the other has a
protein interaction ability that allows it to dimerize
with other estrogen receptor molecules (Umesoso et al.,
1991).

This protein interaction which allows for the

dimerization is essential for stable DNA binding (Umesoso
et al., 1991).

Computer analysis predicts that four amino acids are
in the correct sequence context to be phosphorylated
(Figure 13).

Phosphorylation is a regulatory mechanism

that biochemically alters a protein.

Such a biochemical

modification often functions as an on/off switch, changing
the protein from an inert state to an active one or vice
versa.

Three amino acids Ser-48, Ser-62 and Thr-102 are

potential substrates for phosphorylation by protein kinase

c, a ubiquitous enzyme involved in the regulation of
several signal transduction pathways.

Ser-9 is a
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potential substrate for c-raf, a proto-oncogene involved
with a signal transduction pathway that is associated with
cellular immortalization.
The predicted structural properties suggest that ELAG
may be a nuclear phosphoprotein.

Further, the zinc finger

motif would provide the capability to directly affect
expression of other genes through protein/nucleic acid
interactions.

Direct analysis of the phosphorylation

state of the ELAG protein may be critical in understanding
how the protein activity is regulated.

Phosphorylation/

dephosphorylation is an important cellular mechanism
involved in the regulation of protein activity and
localization (Bishop, 1987).

Given the temporal

characteristics of ELAG expression, I hypothesize that
ELAG provides a signal to the nucleus that continues the
cascade of T cell activation genes and initiates the
transition from Go to G1 of the cell cycle.

Is ELAG a novel oncogene?
ELAG was isolated in an effort to identify novel
oncogenes that are involved in the tumorigenic
transformation of cells Hodgkin's disease and EBV infected
Burkitt•s lymphoma.

Two major mechanisms are involved in

activating oncogenes (Bishop, 1987); 1) increased
expression in oncogenes such as myc and 2) mutationally
altered structure/function of the encoded protein like
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Ras.

To address the possibility that a mutation of ELAG

is a transformation specific event, I was interested in
comparing the sequence of ELAG cDNA isolated from
activated PBMC versus the sequence of ELAG cDNA isolated
from the L428 cell line.

Only ELAG 3 type clones were

isolated from activated PBMCs.

A comparison with the

normal clone shows that L428 derived ELAG 3 does not
encode any mutations in the cDNA (Figure 18).

Therefore,

the potential role of ELAG 3 in transformation would only
be due to constitutive or aberrant expression.
During this investigation I found that ELAG is
expressed as a family of at least four transcripts in the
L428 Hodgkin's-disease cell line.

Sequence analysis

showed that ELAG clones 1, 2, and 3 share the same open
reading frame that encodes a putative 13.2-kDa protein but
have different 3 1 untranslated termini.

ELAG 4 would

encode the same amino terminus as the other 3 ELAG clones
but because of a shortened open reading frame the entire
protein would be only 8.2-kDa and ELAG 4 retains the
putative NLS but would not encode the zinc finger motif.
The role of the various transcripts and encoded proteins
is unknown.

These individual transcripts might be

expressed in the normal counterpart of the Hodgkin's cell,
which as of yet has not been definitively described.

The

various transcripts are potentially expressed in normal
tissues other than activated T cells.

To address this
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possibility, we will have to study ELAG expression in an
expanded panel of cells and tissue types.

If this were

the case one might suggest that expression of all four
isotypes in the L428 cell is potentially a tumor specific
event.

To date, ELAG 4 has not been identified in normal

activated PBMC.

Aberrant expression of the ELAG 4 encoded

protein may represent a tumor specific event.

If this

were the case, one might speculate that the ELAG 4 has a
counter acting effect of a zinc finger-encoding ELAG
protein, and that this counter activity is a critical
deregulatory event that allows that cell to proliferate.
Because ELAG expression is tightly regulated during T
cell activation, it is a good candidate gene that when
aberrantly expressed could contribute to the transformed
phenotype of Hodgkin's disease.

To test this possibility,

ELAG expression was analyzed in several tissue culture
lines.

The data showed that ELAG is expressed at the

greatest levels in the Hodgkin's-disease cell line L428.
Expression was also detected in the EBV infected Burkitt•s
lymphoma cell line Jiyoye but not in P3HR-1, the Jiyoye
derivative.

The Jiyoye cell line is infected with a fully

transforming virus that encodes EBNA 2 (Hinuma and Grace,
1967), a protein that is necessary for the ability of the
virus to immortalize cells.

In contrast, P3HR-1 is

infected with a virus which does not express the EBNA 2
gene due to a deletion in the viral genome and therefore
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is non-transforming (Jeang and Hayward, 1983; Bornkamm et
al., 1982).

Consequently, ELAG may be expressed in

association with a signal transduction pathway that is
involved in Hodgkin's disease as well as transformation by
EBV.

In addition to the analysis of these cell lines, I

showed that ELAG is not expressed at detectable levels in
the African Burkitt•s lymphoma cell line Raji, the T cell
lymphoma line HuT 78, the cervical carcinoma line HeLa, or
the normal lung fibroblast line IMR-90.

In addition, ELAG

expression was not detectable in unstimulated Jurkat
leukemic T cell line (Figure 11) or in unstimulated
peripheral blood mononuclear cells (Figures 8, 9, 10 and
12).

These results suggest that ELAG is very tightly

regulated in most cells but is constitutively expressed in
the Hodgkin's-disease cell line L428 and the African
Burkitt•s lymphoma cell line Jiyoye.

This deregulated

pattern of expression may be associated with the
transformed phenotype of Hodgkin's disease and EBV
transformed cells.

Transcriptional control of ELAG
The transcriptional control region of ELAG was
sequenced in an effort to understand how aberrant signal
could potentially affect ELAG expression in Hodgkin'sdisease cells and also, to investigate the molecular basis
of the transient expression of ELAG in activated T cells.
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ELAG has a TATA-less promoter (Figure 23) which contains
an INR that is 80% identical to the INR described in the
murine TdT gene (Suzow and Friedman, 1993; Smale et al.,
1990).

INR control elements tend to be associated with

tightly regulated genes involved in activation,
differentiation and development (Suzow and Friedman,
1993).

This is consistent with the tight regulation of

ELAG that is observed in activated T cells.
Previous studies have shown that TATA-less genes have
a heterogeneous transcriptional initiation site (Kozmik et
al., 1992).

Primer extension analysis showed multiple

banding near the region that is designated as +1 (Figures
6 and 7) indicating a heterogeneity of transcriptional
initiation.

It is likely that the TATA element found in

most promoters is involved in ensuring that the
transcriptional complex initiates from a single site,
however initiation is more variable in the absence of a
TATA element (Kozmik et al., 1992).
One trans-acting signal that is likely to be involved
in the transcription of ELAG is the Jun/Fos AP-1 complex.
This complex functions by binding to the TPA response
element (TRE) and is involved in transactivating several
genes in response to extracellular stimulus (Holbrook and
Fornace, 1993; Angel and Karin, 1991).

PMA stimulation of

Jurkat cells, which activates AP-1 activity, induces ELAG
expression by four hours (Figure 11).

Additionally, I
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have identified a tandem of TREs at positions -37 and -53
(Figure 23), providing strong evidence that the AP-1
complex is involved in regulation of ELAG expression.

Few

early activation genes have been identified that have a
TRE, thus ELAG may represent one of the few early
activation genes that may be a substrate for the AP-1
complex.

Promoters containing multiple TRE elements have

been shown to be induced to higher levels than promoters
containing only a single element and therefore the role of
AP-1 on ELAG expression may be very important.
A consensus sequence for the binding of the CD28
receptor element (CD28 RE) was identified at position -110
from the designated transcriptional start site (Figure
23).

Recent studies have shown that CD28 is an important

cell surface molecule that transduces a costimulatory
signal from an antigen presenting cell that is likely to
be required for T cell activation (Shaninian et al.,
1993).

CD28 then transactivates cellular genes by

inducing the activity of a nuclear DNA binding protein
(Fraser et al., 1991).

Genes stimulated through the CD28

RE include IL-2 (Fraser et al., 1991), IL-3, GM-CSF, and
interferon-gamma (Fraser and Weiss, 1992).

Definitive

evidence that stimulation of the CD28 RE will augment ELAG
transcription would provide strong support for the notion
that ELAG is essential for T cell activation.
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